Abbott Laboratories (ABT)
Abbott Park, IL, US
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
3 articles
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 1957-03-04 | — | Active |
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.83% | -1.44% | -5.74% | -26.45% | -33.61% | -31.69% | -35.93% | -15.86% | -19.10% | +115.95% | +51,876.92% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | -1 |
| Buy | 16 | 0 |
| Hold | 7 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 7 |
126.86
+37.7%
|
| Last Year | 25 |
137.92
+49.7%
|
| All Time | 70 |
132.83
+44.2%
|
-
Revenue growth Medical - Devices: +11.2%+5.7% Q1'26: +7.8% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-51.3% Q1'26: -18.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+14.2% Q1'26: +8.2% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+19.9% ★ Q1'26: +16.5% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+11.5% ★ Q1'26: +6.9% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-0.1% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.30× Q1'26: 4.62× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 19 Rev. Ana. 16 EPS Ana. |
Dec 2027 19 Rev. Ana. 16 EPS Ana. |
Dec 2028 18 Rev. Ana. 9 EPS Ana. |
Dec 2029 11 Rev. Ana. 3 EPS Ana. |
Dec 2030 9 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
38.85B
est: 38.51B (+0.9%)
|
39.87B
est: 39.30B (+1.5%)
|
21.85B
est: 21.09B (+3.6%)
|
20.25B
est: 19.77B (+2.4%)
|
20.41B
est: 20.44B (-0.2%)
|
20.85B
est: 20.89B (-0.2%)
|
27.39B
est: 27.20B (+0.7%)
|
30.58B
est: 30.67B (-0.3%)
|
31.90B
est: 31.86B (+0.1%)
|
34.61B
est: 33.85B (+2.2%)
|
43.08B
est: 42.32B (+1.8%)
|
43.65B
est: 43.22B (+1.0%)
|
40.11B
est: 40.73B (-1.5%)
|
41.95B
est: 42.00B (-0.1%)
|
44.33B
est: 44.67B (-0.8%)
|
50.40B
50.35B – 50.49B
+12.8% YoY
|
54.94B
54.15B – 55.36B
+9.0% YoY
|
58.93B
58.81B – 59.04B
+7.2% YoY
|
63.43B
61.43B – 63.86B
+7.7% YoY
|
68.25B
66.09B – 68.71B
+7.6% YoY
|
| EBITDA |
9.26B
est: 8.70B (+6.5%)
|
3.50B
est: 9.49B (-63.2%)
|
3.60B
est: 4.41B (-18.4%)
|
4.16B
est: 4.47B (-7.1%)
|
4.83B
est: 6.20B (-22.1%)
|
3.07B
est: 3.45B (-11.0%)
|
6.13B
est: 6.01B (+2.1%)
|
6.88B
est: 6.93B (-0.8%)
|
7.91B
est: 7.66B (+3.3%)
|
9.00B
est: 7.71B (+16.8%)
|
12.16B
est: 10.02B (+21.3%)
|
11.89B
est: 10.75B (+10.6%)
|
10.61B
est: 10.90B (-2.7%)
|
10.83B
est: 11.24B (-3.6%)
|
11.55B
est: 11.95B (-3.3%)
|
13.49B
13.47B – 13.51B
+12.8% YoY
|
14.70B
14.49B – 14.81B
+9.0% YoY
|
15.77B
15.74B – 15.80B
+7.2% YoY
|
16.97B
16.44B – 17.09B
+7.7% YoY
|
18.26B
17.68B – 18.38B
+7.6% YoY
|
| EBIT |
6.22B
est: 5.70B (+9.0%)
|
714.00M
est: 7.97B (-91.0%)
|
2.09B
est: 2.54B (-17.7%)
|
2.68B
est: 2.59B (+3.6%)
|
3.36B
est: 2.74B (+22.7%)
|
1.72B
est: 3.11B (-44.8%)
|
3.11B
est: 1.72B (+80.8%)
|
3.60B
est: 3.61B (-0.4%)
|
4.90B
est: 4.48B (+9.3%)
|
5.68B
est: 4.73B (+20.0%)
|
8.62B
est: 6.83B (+26.2%)
|
8.62B
est: 8.03B (+7.3%)
|
7.36B
est: 7.83B (-6.0%)
|
7.62B
est: 8.08B (-5.7%)
|
8.81B
est: 8.59B (+2.5%)
|
9.69B
9.68B – 9.71B
+12.8% YoY
|
10.56B
10.41B – 10.65B
+9.0% YoY
|
11.33B
11.31B – 11.35B
+7.2% YoY
|
12.20B
11.81B – 12.28B
+7.7% YoY
|
13.12B
12.71B – 13.21B
+7.6% YoY
|
| Net Income |
4.73B
est: 4.69B (+0.9%)
|
5.96B
est: 5.87B (+1.5%)
|
2.58B
est: 2.47B (+4.5%)
|
2.28B
est: 2.14B (+6.9%)
|
4.42B
est: 4.10B (+8.0%)
|
1.40B
est: 1.37B (+2.5%)
|
477.00M
est: 425.71M (+12.0%)
|
2.37B
est: 2.34B (+1.2%)
|
3.69B
est: 3.64B (+1.3%)
|
4.50B
est: 3.98B (+12.9%)
|
7.07B
est: 5.75B (+23.0%)
|
6.93B
est: 6.73B (+3.0%)
|
5.72B
est: 5.54B (+3.4%)
|
13.40B
est: 8.17B (+64.1%)
|
6.52B
est: 9.00B (-27.5%)
|
9.57B
9.55B – 9.60B
+6.3% YoY
|
10.58B
10.42B – 10.74B
+10.5% YoY
|
9.23B
8.68B – 13.67B
-12.7% YoY
|
13.21B
12.66B – 13.32B
+43.1% YoY
|
14.60B
14.00B – 14.73B
+10.5% YoY
|
| SGA |
12.54B
est: 12.64B (-0.8%)
|
7.30B
est: 11.88B (-38.5%)
|
6.34B
est: 6.68B (-5.1%)
|
6.29B
est: 6.29B (-0.1%)
|
6.64B
est: 6.45B (+3.0%)
|
6.64B
est: 6.49B (+2.2%)
|
8.96B
est: 8.73B (+2.6%)
|
9.69B
est: 9.63B (+0.6%)
|
9.69B
est: 9.62B (+0.7%)
|
9.67B
est: 8.21B (+17.8%)
|
11.28B
est: 9.34B (+20.7%)
|
11.11B
est: 9.00B (+23.4%)
|
10.88B
est: 10.95B (-0.6%)
|
11.65B
est: 11.29B (+3.2%)
|
12.38B
est: 12.01B (+3.0%)
|
13.55B
13.54B – 13.58B
+12.8% YoY
|
14.77B
14.56B – 14.89B
+9.0% YoY
|
15.85B
15.82B – 15.88B
+7.2% YoY
|
17.06B
16.52B – 17.17B
+7.7% YoY
|
18.35B
17.77B – 18.48B
+7.6% YoY
|
| EPS |
3.01
est: 4.58 (-34.3%)
|
3.78
est: 4.93 (-23.3%)
|
1.66
est: 1.87 (-11.2%)
|
1.51
est: 2.00 (-24.5%)
|
3.00
est: 2.15 (+39.6%)
|
0.95
est: 2.20 (-56.9%)
|
0.27
est: 2.50 (-89.2%)
|
1.35
est: 2.88 (-53.2%)
|
2.07
est: 3.24 (-36.2%)
|
2.52
est: 3.55 (-29.0%)
|
3.97
est: 5.10 (-22.1%)
|
3.94
est: 5.23 (-24.7%)
|
3.30
est: 3.18 (+3.8%)
|
7.67
est: 4.67 (+64.1%)
|
3.74
est: 5.15 (-27.4%)
|
5.47
5.46 – 5.49
+6.2% YoY
|
6.06
5.97 – 6.14
+10.6% YoY
|
6.75
4.97 – 7.83
+11.5% YoY
|
7.56
7.25 – 7.63
+11.9% YoY
|
8.36
8.01 – 8.43
+10.5% YoY
|
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-27 | BTIG | Buy | Buy | Maintain |
| 2026-04-20 | Barclays | Overweight | Overweight | Maintain |
| 2026-04-17 | Piper Sandler | Overweight | Overweight | Maintain |
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-01 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group - 23-1945930 | 149.15M | 8.43% | — | 2.88M | 141.95M | 7.20M | IA | — | 2022-02-09 | ↗ |
| 2 | (1) BlackRock, Inc. | 137.16M | 7.80% | 121.11M | — | — | — | HC | Delaware | 2022-02-01 | ↗ |
| 3 | Capital Research Global Investors ** | 113.69M | 6.40% | 113.69M | — | — | 113.69M | IA | Delaware | 2020-02-14 | ↗ |
| 4 | ###-##-#### | 92.77M | 5.60% | — | 92.50M | 92.50M | 92.50M | IN | United States | 2003-02-05 | ↗ |
| 5 | BlackRock for purposes of Schedule 13G filings. | 91.72M | 5.93% | 91.72M | — | 91.72M | — | HC | Delaware | 2010-01-29 | ↗ |
| 6 | Abbott Laboratories Stock Retirement Trust | 89.28M | 5.40% | — | — | — | 89.28M | EP | Illinois | 2003-02-05 | ↗ |
| 7 | Amber Acquisition Inc. | 81.91M | 100.00% | — | 81.91M | — | 10.00 | CO | Delaware | 2010-04-21 | ↗ |
| 8 | Rainforest Acquisition Inc. | 9.64M | 15.50% | — | 9.64M | — | 10.00 | CO | Delaware | 2009-01-21 | ↗ |
| 9 | Abbott Investments Luxembourg Sarl | 2.50M | 29.60% | — | 2.50M | — | 10.00 | CO | Luxembourg | 2009-12-23 | ↗ |
| 10 | Scorpio Designated Corporation Ltd. | 2.50M | 29.60% | — | 2.50M | — | 10.00 | CO | Israel | 2009-12-23 | ↗ |
| 11 | 36-0698440 | 1.21M | 2.93% | 1.21M | — | 1.21M | 10.00 | CO | Illinois | 2004-06-21 | ↗ |
| 12 | Abbott Laboratories | 865.6K | 1.70% | 865.6K | — | 865.6K | — | CO | State of Illinois | 2014-02-14 | ↗ |
| 13 | 95-1411037 | 13.00 | 4.90% | 86.37M | — | 86.39M | — | IA | Delaware | 2021-02-16 | ↗ |
| 14 | Abbott Laboratories (36-0698440) | — | 0.00% | — | — | — | — | CO | Illinois | 2010-12-10 | ↗ |
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 175.56M +2.4M (+1.4%) | 22.00B -1.2B (-5.2%) | 10.05% +0.149 pp | 0.32% -0.028 pp | USD52.43 +139.0% | 84 qtrs — |
| 2 | BLACKROCK, INC. | 146.91M +5.3M (+3.8%) | 18.41B -554.3M (-2.9%) | 8.41% +0.315 pp | 0.31% -0.021 pp | USD115.13 +8.8% | 6 qtrs — |
| 3 | STATE STREET CORP | 79.85M +1.6M (+2.1%) | 10.00B -472.7M (-4.5%) | 4.57% +0.098 pp | 0.34% -0.028 pp | USD54.72 +129.0% | 51 qtrs — |
| 4 | CAPITAL INTERNATIONAL INVESTORS | 63.23M +1.6M (+2.6%) | 7.92B -329.5M (-4.0%) | 3.62% +0.097 pp | 1.24% -0.090 pp | USD90.08 +39.1% | 51 qtrs — |
| 5 | CAPITAL RESEARCH GLOBAL INVESTORS | 39.17M +400.4K (+1.0%) | 4.91B -285.2M (-5.5%) | 2.24% +0.026 pp | 0.91% -0.068 pp | USD61.32 +104.3% | 51 qtrs — |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 38.41M -134.4K (-0.3%) | 4.79B -347.6M (-6.8%) | 2.20% -0.005 pp | 0.30% -0.032 pp | USD69.71 +79.7% | 78 qtrs — |
| 7 | MORGAN STANLEY | 36.73M -1.9M (-4.9%) | 4.60B -573.2M (-11.1%) | 2.10% -0.107 pp | 0.27% -0.039 pp | USD86.88 +44.2% | 51 qtrs — |
| 8 | NORGES BANK | 23.46M +23.5M (+100.0%) | 2.94B +2.9B (+100.0%) | 1.34% +1.343 pp | 0.31% +0.314 pp | USD125.29 +0.0% | 1 qtrs NEW |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 23.43M +188.6K (+0.8%) | 2.94B -177.4M (-5.7%) | 1.34% +0.012 pp | 0.51% -0.031 pp | USD108.00 +16.0% | 81 qtrs — |
| 10 | JPMORGAN CHASE & CO | 22.19M -7.2M (-24.5%) | 2.78B -1.2B (-29.3%) | 1.27% -0.410 pp | 0.17% -0.061 pp | USD110.45 +13.4% | 51 qtrs — |
| 11 | BANK OF AMERICA CORP /DE/ | 19.83M -975.2K (-4.7%) | 2.48B -302.2M (-10.8%) | 1.14% -0.055 pp | 0.18% -0.008 pp | USD106.81 +17.3% | 52 qtrs — |
| 12 | NORTHERN TRUST CORP | 19.78M -666.2K (-3.3%) | 2.48B -260.3M (-9.5%) | 1.13% -0.037 pp | 0.32% -0.034 pp | USD47.52 +163.7% | 51 qtrs — |
| 13 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 17.89M +118.0K (+0.7%) | 2.24B -138.9M (-5.8%) | 1.02% +0.008 pp | 1.41% -0.040 pp | USD124.70 +0.5% | 11 qtrs — |
| 14 | WELLS FARGO & COMPANY/MN | 16.29M -422.1K (-2.5%) | 2.04B -197.4M (-8.8%) | 0.93% -0.023 pp | 0.37% -0.054 pp | USD45.97 +172.5% | 57 qtrs — |
| 15 | GOLDMAN SACHS GROUP INC | 15.50M -632.2K (-3.9%) | 1.94B -218.7M (-10.1%) | 0.89% -0.035 pp | 0.24% -0.026 pp | USD100.16 +25.1% | 73 qtrs — |
| 16 | PRICE T ROWE ASSOCIATES INC /MD/ | 14.72M -1.1M (-6.8%) | 1.84B -272.2M (-12.9%) | 0.84% -0.061 pp | 0.20% -0.028 pp | USD126.81 -1.2% | 75 qtrs — |
| 17 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 14.52M -577.6K (-3.8%) | 1.82B -203.0M (-10.0%) | 0.83% -0.032 pp | 0.59% -0.040 pp | USD72.81 +72.1% | 51 qtrs — |
| 18 | STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 13.59M +— (+0.0%) | 1.70B -117.5M (-6.5%) | 0.78% +0.001 pp | 1.34% -0.180 pp | USD22.28 +462.3% | 108 qtrs — |
| 19 | INVESCO LTD. | 13.34M -610.9K (-4.4%) | 1.67B -197.2M (-10.6%) | 0.76% -0.034 pp | 0.26% -0.038 pp | USD109.98 +13.9% | 57 qtrs — |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 13.19M +52.2K (+0.4%) | 1.65B -107.1M (-6.1%) | 0.76% +0.004 pp | 0.26% -0.024 pp | USD66.09 +89.6% | 100 qtrs — |
| 21 | AMERIPRISE FINANCIAL INC | 13.18M -323.6K (-2.4%) | 1.64B -159.3M (-8.8%) | 0.75% -0.018 pp | 0.37% -0.043 pp | USD97.17 +28.9% | 55 qtrs — |
| 22 | BANK OF NEW YORK MELLON CORP | 12.93M +247.7K (+2.0%) | 1.62B -78.6M (-4.6%) | 0.74% +0.015 pp | 0.29% -0.042 pp | USD80.28 +56.1% | 66 qtrs — |
| 23 | LEGAL & GENERAL GROUP PLC | 12.62M -279.8K (-2.2%) | 1.58B -146.6M (-8.5%) | 0.72% -0.015 pp | 0.35% -0.037 pp | USD70.06 +78.8% | 75 qtrs — |
| 24 | ALLIANCEBERNSTEIN L.P. | 12.45M +6.9M (+125.3%) | 1.56B +820.0M (+110.8%) | 0.71% +0.397 pp | 0.49% +0.260 pp | USD111.35 +12.5% | 61 qtrs — |
| 25 | NUVEEN, LLC | 11.79M +140.2K (+1.2%) | 1.48B -83.2M (-5.3%) | 0.68% +0.009 pp | 0.39% -0.025 pp | USD132.56 -5.5% | 4 qtrs — |
| 26 | DEUTSCHE BANK AG\ | 11.58M +934.8K (+8.8%) | 1.45B +25.0M (+1.8%) | 0.66% +0.054 pp | 0.47% -0.005 pp | USD101.54 +23.4% | 50 qtrs — |
| 27 | FISHER ASSET MANAGEMENT, LLC | 11.44M -592.6K (-4.9%) | 1.43B -178.3M (-11.1%) | 0.65% -0.033 pp | 0.49% -0.094 pp | USD98.58 +27.1% | 57 qtrs — |
| 28 | FRANKLIN RESOURCES INC | 11.16M +851.8K (+8.3%) | 1.40B +18.3M (+1.3%) | 0.64% +0.049 pp | 0.34% -0.001 pp | USD76.94 +62.8% | 51 qtrs — |
| 29 | UBS ASSET MANAGEMENT AMERICAS INC | 11.06M +602.4K (+5.8%) | 1.39B -15.0M (-1.1%) | 0.63% +0.035 pp | 0.29% -0.011 pp | USD103.18 +21.4% | 90 qtrs — |
| 30 | UBS GROUP AG | 10.48M +665.4K (+6.8%) | 1.31B -1.5M (-0.1%) | 0.60% +0.039 pp | 0.21% +0.007 pp | USD100.10 +25.2% | 45 qtrs — |
| 31 | FMR LLC | 9.63M -2.0M (-17.0%) | 1.21B -346.5M (-22.3%) | 0.55% -0.112 pp | 0.06% -0.019 pp | USD105.74 +18.5% | 70 qtrs — |
| 32 | DIMENSIONAL FUND ADVISORS LP | 9.04M +17.1K (+0.2%) | 1.13B -75.8M (-6.3%) | 0.52% +0.002 pp | 0.24% -0.022 pp | USD81.23 +54.2% | 51 qtrs — |
| 33 | GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC | 8.48M +306.1K (+3.7%) | 1.06B -32.4M (-3.0%) | 0.49% +0.018 pp | 2.72% -0.372 pp | USD103.19 +21.4% | 69 qtrs — |
| 34 | CAPITAL WORLD INVESTORS | 8.47M -460.2K (-5.2%) | 1.06B -134.9M (-11.3%) | 0.48% -0.026 pp | 0.14% -0.019 pp | USD129.90 -3.5% | 6 qtrs — |
| 35 | AMUNDI | 8.19M +1.8M (+28.3%) | 1.03B +172.1M (+20.2%) | 0.47% +0.104 pp | 0.28% +0.004 pp | USD114.71 +9.2% | 19 qtrs — |
| 36 | JANUS HENDERSON GROUP PLC | 7.45M +952.9K (+14.7%) | 933.60M +63.2M (+7.3%) | 0.43% +0.055 pp | 0.42% +0.021 pp | USD97.87 +28.0% | 88 qtrs — |
| 37 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 7.00M +99.0K (+1.4%) | 869.13M -55.0M (-5.9%) | 0.40% +0.006 pp | 0.59% -0.076 pp | USD105.34 +18.9% | 58 qtrs — |
| 38 | FLOSSBACH VON STORCH AG | 6.46M -152.3K (-2.3%) | 809.08M -76.3M (-8.6%) | 0.37% -0.008 pp | 3.21% -0.281 pp | USD89.50 +40.0% | 46 qtrs — |
| 39 | ROYAL BANK OF CANADA | 6.25M +98.8K (+1.6%) | 783.62M -40.9M (-5.0%) | 0.36% +0.006 pp | 0.13% -0.008 pp | USD85.44 +46.6% | 51 qtrs — |
| 40 | ENVESTNET ASSET MANAGEMENT INC | 5.46M -181.7K (-3.2%) | 684.51M -71.6M (-9.5%) | 0.31% -0.010 pp | 0.20% -0.015 pp | USD105.94 +18.3% | 51 qtrs — |
| 41 | RAYMOND JAMES FINANCIAL INC | 5.41M -129.6K (-2.3%) | 677.85M -63.7M (-8.6%) | 0.31% -0.007 pp | 0.21% -0.028 pp | USD113.52 +10.4% | 5 qtrs — |
| 42 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 5.21M +1.2M (+29.7%) | 652.33M +114.8M (+21.4%) | 0.30% +0.069 pp | 0.37% +0.051 pp | USD98.63 +27.0% | 53 qtrs — |
| 43 | DIAMOND HILL CAPITAL MANAGEMENT INC | 5.17M -434.1K (-7.7%) | 647.69M -102.9M (-13.7%) | 0.30% -0.025 pp | 3.32% -0.245 pp | USD60.70 +106.4% | 85 qtrs — |
| 44 | SWISS NATIONAL BANK | 4.77M -245.9K (-4.9%) | 597.56M -74.2M (-11.0%) | 0.27% -0.014 pp | 0.36% -0.034 pp | USD66.92 +87.2% | 51 qtrs — |
| 45 | NEUBERGER BERMAN GROUP LLC | 4.76M -481.0K (-9.2%) | 595.80M -105.5M (-15.0%) | 0.27% -0.027 pp | 0.44% -0.069 pp | USD121.26 +3.3% | 67 qtrs — |
| 46 | ACADIAN ASSET MANAGEMENT LLC | 4.68M +820.6K (+21.3%) | 586.55M +69.4M (+13.4%) | 0.27% +0.047 pp | 0.96% +0.061 pp | USD127.74 -1.9% | 23 qtrs — |
| 47 | PNC FINANCIAL SERVICES GROUP, INC. | 4.66M +83.4K (+1.8%) | 584.33M -29.2M (-4.8%) | 0.27% +0.005 pp | 0.32% -0.053 pp | USD51.63 +142.7% | 51 qtrs — |
| 48 | FIRST TRUST ADVISORS LP | 4.54M +669.5K (+17.3%) | 569.27M +50.4M (+9.7%) | 0.26% +0.039 pp | 0.41% +0.027 pp | USD129.43 -3.2% | 51 qtrs — |
| 49 | FAYEZ SAROFIM & CO | 4.48M -35.4K (-0.8%) | 561.36M -47.8M (-7.8%) | 0.26% -0.002 pp | 1.35% -0.065 pp | USD64.32 +94.8% | 49 qtrs — |
| 50 | ALLIANZ ASSET MANAGEMENT GMBH | 4.23M +604.3K (+16.7%) | 530.45M +44.3M (+9.1%) | 0.24% +0.035 pp | 0.54% -0.006 pp | USD111.34 +12.5% | 51 qtrs — |
| 51 | HSBC HOLDINGS PLC | 4.06M +235.3K (+6.1%) | 509.45M -3.0M (-0.6%) | 0.23% +0.014 pp | 0.26% -0.023 pp | USD96.63 +29.7% | 56 qtrs — |
| 52 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 4.03M -165.6K (-4.0%) | 504.31M -57.0M (-10.2%) | 0.23% -0.009 pp | 0.30% -0.027 pp | USD61.72 +103.0% | 59 qtrs — |
| 53 | NATIONAL PENSION SERVICE | 4.02M +457.3K (+12.8%) | 504.05M +26.4M (+5.5%) | 0.23% +0.026 pp | 0.37% +0.002 pp | USD87.20 +43.7% | 46 qtrs — |
| 54 | POLEN CAPITAL MANAGEMENT LLC | 3.96M -3.5M (-46.6%) | 496.43M -497.5M (-50.1%) | 0.23% -0.198 pp | 2.12% -1.107 pp | USD93.42 +34.1% | 26 qtrs — |
| 55 | STIFEL FINANCIAL CORP | 3.95M +2.2M (+122.0%) | 494.61M +256.4M (+107.6%) | 0.23% +0.124 pp | 0.44% +0.227 pp | USD101.00 +24.0% | 48 qtrs — |
| 56 | CIBC PRIVATE WEALTH GROUP, LLC | 3.93M -83.8K (-2.1%) | 492.68M -45.2M (-8.4%) | 0.23% -0.005 pp | 0.83% -0.088 pp | USD93.84 +33.5% | 48 qtrs — |
| 57 | PRINCIPAL FINANCIAL GROUP INC | 3.61M -315.7K (-8.0%) | 452.02M -73.5M (-14.0%) | 0.21% -0.018 pp | 0.23% -0.034 pp | USD61.54 +103.6% | 81 qtrs — |
| 58 | KBC GROUP NV | 2.32M +1.3M (+127.3%) | 430.43M +293.7M (+214.7%) | 0.13% +0.074 pp | 0.98% +0.654 pp | USD121.58 +3.1% | 68 qtrs — |
| 59 | VONTOBEL HOLDING LTD. | 3.38M -1.6M (-32.0%) | 424.01M -242.4M (-36.4%) | 0.19% -0.091 pp | 1.34% -0.677 pp | USD106.79 +17.3% | 21 qtrs — |
| 60 | BARCLAYS PLC | 3.18M -1.2M (-28.0%) | 398.71M -104.9M (-20.8%) | 0.18% -0.070 pp | 0.10% -0.034 pp | USD120.73 +3.8% | 51 qtrs — |
| 61 | WELLCOME TRUST LTD (THE) AS TRUSTEE OF THE WELLCOME TRUST | 3.13M +— (+0.0%) | 391.53M -27.0M (-6.5%) | 0.18% +0.000 pp | 4.20% -0.354 pp | USD96.06 +30.4% | 23 qtrs — |
| 62 | RATHBONES GROUP PLC | 3.12M +107.6K (+3.6%) | 390.45M -12.5M (-3.1%) | 0.18% +0.006 pp | 1.55% -0.091 pp | USD102.08 +22.7% | 60 qtrs — |
| 63 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 3.06M +93.5K (+3.2%) | 383.13M -13.8M (-3.5%) | 0.18% +0.006 pp | 0.31% -0.011 pp | USD90.36 +38.7% | 104 qtrs — |
| 64 | RHUMBLINE ADVISERS | 2.98M -57.5K (-1.9%) | 373.23M -33.5M (-8.2%) | 0.17% -0.003 pp | 0.30% -0.025 pp | USD51.21 +144.7% | 51 qtrs — |
| 65 | BNP PARIBAS ARBITRAGE, SNC | 2.96M +365.2K (+14.1%) | 370.76M +23.3M (+6.7%) | 0.17% +0.021 pp | 0.17% -0.018 pp | USD113.53 +10.4% | 51 qtrs — |
| 66 | BANK OF MONTREAL /CAN/ | 2.96M +360.9K (+13.9%) | 370.64M +22.8M (+6.5%) | 0.17% +0.021 pp | 0.13% -0.005 pp | USD98.68 +27.0% | 51 qtrs — |
| 67 | US BANCORP \DE\ | 2.78M -53.4K (-1.9%) | 348.20M -31.2M (-8.2%) | 0.16% -0.003 pp | 0.41% -0.042 pp | USD47.33 +164.7% | 51 qtrs — |
| 68 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 2.74M -31.0K (-1.1%) | 343.64M -27.9M (-7.5%) | 0.16% -0.002 pp | 0.34% -0.037 pp | USD46.53 +169.3% | 55 qtrs — |
| 69 | NINETY ONE UK LTD | 2.69M +2.7M (+100.0%) | 336.81M +336.8M (+100.0%) | 0.15% +0.154 pp | 0.72% +0.722 pp | USD125.29 +0.0% | 1 qtrs NEW |
| 70 | BANK JULIUS BAER & CO. LTD, ZURICH | 2.55M +1.1M (+77.8%) | 319.10M +127.3M (+66.4%) | 0.15% +0.064 pp | 0.88% +0.340 pp | USD120.66 +3.8% | 24 qtrs — |
| 71 | DEKABANK DEUTSCHE GIROZENTRALE | 2.54M +— (+0.0%) | 298.89M -39.0M (-11.5%) | 0.15% +0.000 pp | 0.52% -0.052 pp | USD97.45 +28.6% | 66 qtrs — |
| 72 | 1832 ASSET MANAGEMENT L.P. | 2.37M +2.2M (+1,095.7%) | 297.40M +270.8M (+1,018.5%) | 0.14% +0.125 pp | 0.23% +0.206 pp | USD124.85 +0.4% | 53 qtrs — |
| 73 | ENSIGN PEAK ADVISORS, INC | 2.36M -916.8K (-28.0%) | 295.58M -143.2M (-32.6%) | 0.14% -0.052 pp | 0.52% -0.198 pp | USD96.50 +29.8% | 25 qtrs — |
| 74 | AVIVA PLC | 2.28M +36.1K (+1.6%) | 285.92M -14.9M (-5.0%) | 0.13% +0.002 pp | 0.48% -0.065 pp | USD114.61 +9.3% | 51 qtrs — |
| 75 | LPL FINANCIAL LLC | 2.17M +193.2K (+9.8%) | 271.74M +7.1M (+2.7%) | 0.12% +0.011 pp | 0.07% -0.003 pp | USD102.51 +22.2% | 51 qtrs — |
| 76 | CI PRIVATE WEALTH, LLC | 2.11M +35.5K (+1.7%) | 264.32M -13.0M (-4.7%) | 0.12% +0.002 pp | 0.36% -0.082 pp | USD110.56 +13.3% | 13 qtrs — |
| 77 | CITADEL ADVISORS LLC | 2.08M +1.5M (+255.1%) | 260.61M +182.1M (+232.1%) | 0.12% +0.086 pp | 0.04% +0.027 pp | USD127.73 -1.9% | 2 qtrs — |
| 78 | BAIRD FINANCIAL GROUP, INC. | 2.00M -12.2K (-0.6%) | 250.08M -18.9M (-7.0%) | 0.11% -0.001 pp | 0.39% -0.043 pp | USD75.62 +65.7% | 43 qtrs — |
| 79 | ABRDN PLC | 1.99M +23.8K (+1.2%) | 249.77M -12.3M (-4.7%) | 0.11% +0.002 pp | 0.39% -0.028 pp | USD112.84 +11.0% | 34 qtrs — |
| 80 | NEW YORK STATE COMMON RETIREMENT FUND | 1.98M -49.7K (-2.4%) | 248.41M -23.8M (-8.7%) | 0.11% -0.003 pp | 0.33% -0.021 pp | USD32.33 +287.5% | 103 qtrs — |
| 81 | CANADA PENSION PLAN INVESTMENT BOARD | 1.90M +283.6K (+17.6%) | 237.71M +21.6M (+10.0%) | 0.11% +0.016 pp | 0.16% +0.007 pp | USD114.42 +9.5% | 52 qtrs — |
| 82 | CITIGROUP INC | 1.89M -1.8M (-48.2%) | 237.09M -252.5M (-51.6%) | 0.11% -0.101 pp | 0.10% -0.114 pp | USD110.84 +13.0% | 108 qtrs — |
| 83 | CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 1.88M +420.1K (+28.8%) | 235.37M +40.0M (+20.5%) | 0.11% +0.024 pp | 0.40% +0.047 pp | USD126.83 -1.2% | 51 qtrs — |
| 84 | JENSEN INVESTMENT MANAGEMENT INC | 1.87M -536.4K (-22.3%) | 234.68M -88.0M (-27.3%) | 0.11% -0.031 pp | 3.69% -0.312 pp | USD129.89 -3.5% | 51 qtrs — |
| 85 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 1.87M -318.6K (-14.5%) | 234.67M -56.9M (-19.5%) | 0.11% -0.018 pp | 0.41% -0.009 pp | USD105.93 +18.3% | 63 qtrs — |
| 86 | MARINER, LLC | 1.84M -54.4K (-2.9%) | 230.41M -23.2M (-9.1%) | 0.11% -0.003 pp | 0.27% -0.053 pp | USD113.31 +10.6% | 56 qtrs — |
| 87 | HIGHTOWER ADVISORS, LLC | 1.83M -6.6K (-0.4%) | 229.50M -16.7M (-6.8%) | 0.10% 0.000 pp | 0.25% -0.029 pp | USD101.08 +24.0% | 67 qtrs — |
| 88 | B. METZLER SEEL. SOHN & CO. AG | 1.81M +52.9K (+3.0%) | 226.50M -8.4M (-3.6%) | 0.10% +0.003 pp | 1.98% -0.096 pp | USD123.60 +1.4% | 17 qtrs — |
| 89 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.74M +603.0K (+53.0%) | 218.23M +65.7M (+43.1%) | 0.10% +0.035 pp | 0.13% +0.032 pp | USD128.40 -2.4% | 24 qtrs — |
| 90 | LORD, ABBETT & CO. LLC | 1.72M -364.3K (-17.5%) | 215.53M -63.7M (-22.8%) | 0.10% -0.021 pp | 0.66% -0.170 pp | USD114.18 +9.7% | 38 qtrs — |
| 91 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.68M -615.8K (-26.8%) | 210.64M -97.0M (-31.5%) | 0.10% -0.035 pp | 0.32% -0.169 pp | USD102.07 +22.7% | 64 qtrs — |
| 92 | TD ASSET MANAGEMENT INC | 1.65M -1.4M (-45.5%) | 206.80M -199.0M (-49.0%) | 0.09% -0.079 pp | 0.17% -0.163 pp | USD116.81 +7.3% | 51 qtrs — |
| 93 | NATIXIS ADVISORS, L.P. | 1.58M -184.7K (-10.4%) | 198.54M -38.4M (-16.2%) | 0.09% -0.011 pp | 0.28% -0.064 pp | USD104.48 +19.9% | 57 qtrs — |
| 94 | CERITY PARTNERS LLC | 1.58M +49.3K (+3.2%) | 197.91M -7.1M (-3.4%) | 0.09% +0.003 pp | 0.29% -0.044 pp | USD116.87 +7.2% | 36 qtrs — |
| 95 | BLAIR WILLIAM & CO/IL | 1.58M -20.4K (-1.3%) | 197.68M -16.4M (-7.7%) | 0.09% -0.001 pp | 0.53% -0.039 pp | USD75.27 +66.5% | 51 qtrs — |
| 96 | COLONY GROUP, LLC | 1.58M +1.0M (+197.0%) | 197.57M +126.6M (+178.3%) | 0.09% +0.060 pp | 0.23% +0.111 pp | USD120.73 +3.8% | 9 qtrs — |
| 97 | PROSHARE ADVISORS LLC | 1.57M -67.1K (-4.1%) | 196.94M -22.6M (-10.3%) | 0.09% -0.004 pp | 0.35% -0.112 pp | USD86.28 +45.2% | 77 qtrs — |
| 98 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | 1.65M -23.0K (-1.4%) | 178.30M -32.7M (-15.5%) | 0.09% -0.001 pp | 1.62% -0.235 pp | USD31.96 +292.0% | 83 qtrs — |
| 99 | J. STERN & CO. LLP | 39.32M +39.0M (+12,439.6%) | 39.32M -2.7M (-6.4%) | 2.25% +2.233 pp | 3.35% +0.173 pp | USD125.14 +0.1% | 9 qtrs — |
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Moreland Mary K | Officer | I-Discretionary | A | Common shares without par value | 5,314 | 94.41 | 501.7K | 17,159 | I | ↗ |
| 2026-04-27 | STARKS DANIEL J | Director | P-Purchase | A | Common shares without par value | 10,000 | 92.65 | 926.5K | 6,751,103 | D | ↗ |
| 2026-04-24 | Stratton John G | Director | A-Award | A | Common shares without par value | 2,286 | 0.00 | — | 21,319 | D | ↗ |
| 2026-04-24 | STARKS DANIEL J | Director | A-Award | A | Option (right to buy) | 7,105 | 91.86 | 652.7K | 7,105 | D | ↗ |
| 2026-04-24 | Roman Michael F | Director | A-Award | A | Common shares without par value | 2,286 | 0.00 | — | 10,764 | D | ↗ |
| 2026-04-24 | O'Grady Michael | Director | A-Award | A | Option (right to buy) | 5,929 | 91.86 | 544.6K | 5,929 | D | ↗ |
| 2026-04-24 | McKinstry Nancy | Director | A-Award | A | Option (right to buy) | 2,305 | 91.86 | 211.7K | 2,305 | D | ↗ |
| 2026-04-24 | McDew Darren W | Director | A-Award | A | Common shares without par value | 2,286 | 0.00 | — | 12,678 | D | ↗ |
| 2026-04-24 | Kumbier Michelle | Director | A-Award | A | Common shares without par value | 2,286 | 0.00 | — | 18,000 | D | ↗ |
| 2026-04-24 | Gonzalez Patricia Paola | Director | A-Award | A | Common shares without par value | 2,286 | 0.00 | — | 9,205 | D | ↗ |
| 2026-04-24 | Conroy Kevin T | Director | — | — | Common shares without par value | 0 | 0.00 | — | 131,451 | D | ↗ |
| 2026-04-24 | Blount Sally E. | Director | A-Award | A | Common shares without par value | 2,286 | 0.00 | — | 36,344 | D | ↗ |
| 2026-04-24 | Babineaux-Fontenot Claire | Director | A-Award | A | Common shares without par value | 2,286 | 0.00 | — | 7,603 | D | ↗ |
| 2026-04-24 | Ahuja Nita | Director | A-Award | A | Common shares without par value | 2,286 | 0.00 | — | 2,286 | D | ↗ |
| 2026-04-23 | Boudreau Philip P | Officer | I-Discretionary | A | Common shares without par value | 8,909 | 92.04 | 820.0K | 9,276 | I | ↗ |
| 2026-03-31 | Stratton John G | Director | A-Award | A | Stock Equivalent Units | 382 | 0.00 | — | 13,489 | D | ↗ |
| 2026-03-31 | Roman Michael F | Director | A-Award | A | Stock Equivalent Units | 367 | 0.00 | — | 6,283 | D | ↗ |
| 2026-03-31 | Gonzalez Patricia Paola | Director | A-Award | A | Stock Equivalent Units | 321 | 0.00 | — | 5,558 | D | ↗ |
| 2026-03-31 | Alpern Robert J | Director | A-Award | A | Stock Equivalent Units | 76 | 0.00 | — | 10,544 | D | ↗ |
| 2026-03-31 | Ahuja Nita | Director | A-Award | A | Stock Equivalent Units | 102 | 0.00 | — | 102 | D | ↗ |
| 2026-03-23 | ORVILLE JACOB A | Officer | — | — | Common shares without par value | 0 | 0.00 | — | 37,238 | D | ↗ |
| 2026-03-02 | Shroff Eric | Officer | S-Sale | D | Common shares without par value | 709 | 115.58 | 81.9K | 39,164 | D | ↗ |
| 2026-03-02 | Salvadori Daniel Gesua Sive | Officer | S-Sale | D | Common shares without par value | 885 | 115.58 | 102.3K | 146,377 | D | ↗ |
| 2026-03-02 | Morrone Louis H. | Officer | S-Sale | D | Common shares without par value | 1,144 | 115.58 | 132.2K | 76,843 | D | ↗ |
| 2026-03-02 | Moreland Mary K | Officer | S-Sale | D | Common shares without par value | 613 | 115.58 | 70.9K | 104,291 | D | ↗ |
| 2026-03-02 | MCCOY JOHN A. JR. | Officer | S-Sale | D | Common shares without par value | 585 | 115.58 | 67.6K | 24,628 | D | ↗ |
| 2026-03-02 | Cushman Elizabeth C. | Officer | S-Sale | D | Common shares without par value | 263 | 115.58 | 30.4K | 38,573 | D | ↗ |
| 2026-02-27 | Shroff Eric | Officer | F-InKind | D | Common shares without par value | 1,384 | 116.26 | 160.9K | 39,873 | D | ↗ |
| 2026-02-27 | Scoggins Christopher J | Officer | F-InKind | D | Common shares without par value | 4,997 | 116.26 | 581.0K | 77,126 | D | ↗ |
| 2026-02-27 | Salvadori Daniel Gesua Sive | Officer | F-InKind | D | Common shares without par value | 6,615 | 116.26 | 769.1K | 147,262 | D | ↗ |
| 2026-02-27 | Morrone Louis H. | Officer | F-InKind | D | Common shares without par value | 4,040 | 116.26 | 469.7K | 77,987 | D | ↗ |
| 2026-02-27 | Moreland Mary K | Officer | F-InKind | D | Common shares without par value | 4,630 | 116.26 | 538.3K | 104,904 | D | ↗ |
| 2026-02-27 | MCCOY JOHN A. JR. | Officer | F-InKind | D | Common shares without par value | 1,142 | 116.26 | 132.8K | 25,213 | D | ↗ |
| 2026-02-27 | Ford Robert B | Director / Officer | F-InKind | D | Common shares without par value | 30,308 | 116.26 | 3.52M | 306,461 | D | ↗ |
| 2026-02-27 | Earnhardt Lisa D | Officer | F-InKind | D | Common shares without par value | 8,577 | 116.26 | 997.2K | 90,407 | D | ↗ |
| 2026-02-27 | Cushman Elizabeth C. | Officer | F-InKind | D | Common shares without par value | 1,421 | 116.26 | 165.2K | 38,836 | D | ↗ |
| 2026-02-27 | Boudreau Philip P | Officer | F-InKind | D | Common shares without par value | 7,441 | 116.26 | 865.1K | 71,172 | D | ↗ |
| 2026-02-24 | Shroff Eric | Officer | A-Award | A | Option (right to buy) | 44,821 | 114.60 | 5.14M | 44,821 | D | ↗ |
| 2026-02-24 | Scoggins Christopher J | Officer | A-Award | A | Option (right to buy) | 76,273 | 114.60 | 8.74M | 76,273 | D | ↗ |
| 2026-02-24 | Salvadori Daniel Gesua Sive | Officer | A-Award | A | Common shares without par value | 21,644 | 0.00 | — | 153,877 | D | ↗ |
| 2026-02-24 | Morrone Louis H. | Officer | A-Award | A | Option (right to buy) | 63,561 | 114.60 | 7.28M | 63,561 | D | ↗ |
| 2026-02-24 | Moreland Mary K | Officer | A-Award | A | Option (right to buy) | 57,512 | 114.60 | 6.59M | 57,512 | D | ↗ |
| 2026-02-24 | MCCOY JOHN A. JR. | Officer | A-Award | A | Option (right to buy) | 22,151 | 114.60 | 2.54M | 22,151 | D | ↗ |
| 2026-02-24 | Ford Robert B | Director / Officer | A-Award | A | Option (right to buy) | 344,066 | 114.60 | 39.43M | 344,066 | D | ↗ |
| 2026-02-24 | Earnhardt Lisa D | Officer | A-Award | A | Common shares without par value | 27,056 | 0.00 | — | 98,984 | D | ↗ |
| 2026-02-24 | Cushman Elizabeth C. | Officer | A-Award | A | Option (right to buy) | 61,964 | 114.60 | 7.10M | 61,964 | D | ↗ |
| 2026-02-24 | Boudreau Philip P | Officer | A-Award | A | Option (right to buy) | 115,413 | 114.60 | 13.23M | 115,413 | D | ↗ |
| 2026-02-04 | STARKS DANIEL J | Director | P-Purchase | A | Common shares without par value | 5,033 | 108.33 | 545.2K | 6,738,817 | D | ↗ |
| 2026-01-23 | Ford Robert B | Director / Officer | P-Purchase | A | Common shares without par value | 18,800 | 107.13 | 2.01M | 216,203 | I | ↗ |
| 2025-12-31 | Stratton John G | Director | A-Award | A | Stock Equivalent Units | 313 | 0.00 | — | 13,034 | D | ↗ |
| 2025-12-31 | Roman Michael F | Director | A-Award | A | Stock Equivalent Units | 301 | 0.00 | — | 5,882 | D | ↗ |
| 2025-12-31 | Gonzalez Patricia Paola | Director | A-Award | A | Stock Equivalent Units | 263 | 0.00 | — | 5,208 | D | ↗ |
| 2025-12-31 | Alpern Robert J | Director | A-Award | A | Stock Equivalent Units | 62 | 0.00 | — | 10,409 | D | ↗ |
| 2025-12-12 | Scoggins Christopher J | Officer | — | — | Option (right to buy) | 51,557 | 75.90 | 3.91M | 0 | D | ↗ |
| 2025-12-12 | Ahuja Nita | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-11 | Salvadori Daniel Gesua Sive | Officer | G-Gift | D | Common shares without par value | 1,536 | 123.28 | 189.4K | 132,233 | D | ↗ |
| 2025-11-25 | Shroff Eric | Officer | S-Sale | D | Common shares without par value | 1,586 | 128.02 | 203.0K | 30,384 | D | ↗ |
| 2025-09-30 | Stratton John G | Director | A-Award | A | Stock Equivalent Units | 293 | 0.00 | — | 12,663 | D | ↗ |
| 2025-09-30 | Roman Michael F | Director | A-Award | A | Stock Equivalent Units | 281 | 0.00 | — | 5,556 | D | ↗ |
| 2025-09-30 | Gonzalez Patricia Paola | Director | A-Award | A | Stock Equivalent Units | 246 | 0.00 | — | 4,922 | D | ↗ |
| 2025-09-30 | Alpern Robert J | Director | A-Award | A | Stock Equivalent Units | 58 | 0.00 | — | 10,300 | D | ↗ |
| 2025-09-01 | MCCOY JOHN A. JR. | Officer | F-InKind | D | Common shares without par value | 79 | 132.66 | 10.5K | 20,982 | D | ↗ |
| 2025-09-01 | Boudreau Philip P | Officer | F-InKind | D | Common shares without par value | 387 | 132.66 | 51.3K | 50,616 | D | ↗ |
| 2025-08-08 | Boudreau Philip P | Officer | S-Sale | D | Common shares without par value | 5,550 | 134.55 | 746.8K | 51,003 | D | ↗ |
| 2025-06-30 | Stratton John G | Director | A-Award | A | Stock Equivalent Units | 282 | 0.00 | — | 12,315 | D | ↗ |
| 2025-06-30 | Roman Michael F | Director | A-Award | A | Stock Equivalent Units | 271 | 0.00 | — | 5,250 | D | ↗ |
| 2025-06-30 | Morrone Louis H. | Officer | F-InKind | D | Common shares without par value | 269 | 134.38 | 36.1K | 66,609 | D | ↗ |
| 2025-06-30 | Gonzalez Patricia Paola | Director | A-Award | A | Stock Equivalent Units | 242 | 0.00 | — | 4,655 | D | ↗ |
| 2025-06-30 | Alpern Robert J | Director | A-Award | A | Stock Equivalent Units | 57 | 0.00 | — | 10,195 | D | ↗ |
| 2025-06-27 | Cushman Elizabeth C. | Officer | — | — | Option (right to buy) | 9,717 | 116.98 | 1.14M | 0 | D | ↗ |
| 2025-04-30 | Blount Sally E. | Director | S-Sale | D | Common shares without par value | 2,600 | 129.66 | 337.1K | 34,058 | D | ↗ |
| 2025-04-25 | Stratton John G | Director | A-Award | A | Common shares without par value | 1,635 | 0.00 | — | 19,033 | D | ↗ |
| 2025-04-25 | STARKS DANIEL J | Director | A-Award | A | Common shares without par value | 1,635 | 0.00 | — | 6,728,817 | D | ↗ |
| 2025-04-25 | Roman Michael F | Director | A-Award | A | Common shares without par value | 1,635 | 0.00 | — | 8,478 | D | ↗ |
| 2025-04-25 | O'Grady Michael | Director | A-Award | A | Common shares without par value | 1,635 | 0.00 | — | 5,317 | D | ↗ |
| 2025-04-25 | McKinstry Nancy | Director | A-Award | A | Common shares without par value | 1,635 | 0.00 | — | 38,724 | D | ↗ |
| 2025-04-25 | McDew Darren W | Director | A-Award | A | Common shares without par value | 1,635 | 0.00 | — | 10,392 | D | ↗ |
| 2025-04-25 | Kumbier Michelle | Director | A-Award | A | Common shares without par value | 1,635 | 0.00 | — | 15,714 | D | ↗ |
| 2025-04-25 | Gonzalez Patricia Paola | Director | A-Award | A | Common shares without par value | 1,635 | 0.00 | — | 6,919 | D | ↗ |
| 2025-04-25 | Blount Sally E. | Director | A-Award | A | Common shares without par value | 1,635 | 0.00 | — | 36,658 | D | ↗ |
| 2025-04-25 | Babineaux-Fontenot Claire | Director | A-Award | A | Common shares without par value | 1,635 | 0.00 | — | 5,317 | D | ↗ |
| 2025-04-25 | Alpern Robert J | Director | A-Award | A | Common shares without par value | 1,635 | 0.00 | — | 40,798 | D | ↗ |
| 2025-03-31 | Stratton John G | Director | A-Award | A | Stock Equivalent Units | 277 | 0.00 | — | 11,979 | D | ↗ |
| 2025-03-31 | Roman Michael F | Director | A-Award | A | Stock Equivalent Units | 265 | 0.00 | — | 4,957 | D | ↗ |
| 2025-03-31 | Gonzalez Patricia Paola | Director | A-Award | A | Stock Equivalent Units | 248 | 0.00 | — | 4,393 | D | ↗ |
| 2025-03-31 | Alpern Robert J | Director | A-Award | A | Stock Equivalent Units | 59 | 0.00 | — | 10,093 | D | ↗ |
| 2025-03-07 | Earnhardt Lisa D | Officer | M-Exempt | A | Common shares without par value | 200 | 80.98 | 16.2K | 72,128 | D | ↗ |
| 2025-03-06 | Earnhardt Lisa D | Officer | M-Exempt | A | Common shares without par value | 91,167 | 80.98 | 7.38M | 163,095 | D | ↗ |
| 2025-03-03 | Wainer Andrea F | Officer | S-Sale | D | Common shares without par value | 949 | 138.17 | 131.1K | 74,381 | D | ↗ |
| 2025-03-03 | Shroff Eric | Officer | S-Sale | D | Common shares without par value | 562 | 138.17 | 77.7K | 31,970 | D | ↗ |
| 2025-03-03 | Morrone Louis H. | Officer | S-Sale | D | Common shares without par value | 1,111 | 138.17 | 153.5K | 66,878 | D | ↗ |
| 2025-03-03 | Moreland Mary K | Officer | S-Sale | D | Common shares without par value | 791 | 138.17 | 109.3K | 95,583 | D | ↗ |
| 2025-03-03 | MCCOY JOHN A. JR. | Officer | S-Sale | D | Common shares without par value | 562 | 138.17 | 77.7K | 21,061 | D | ↗ |
| 2025-03-01 | Shroff Eric | Officer | — | — | Option (right to buy) | 13,056 | 106.24 | 1.39M | 0 | D | ↗ |
| 2025-02-28 | Wainer Andrea F | Officer | F-InKind | D | Common shares without par value | 7,313 | 135.87 | 993.6K | 75,330 | D | ↗ |
| 2025-02-28 | Salvadori Daniel Gesua Sive | Officer | F-InKind | D | Common shares without par value | 8,462 | 135.87 | 1.15M | 133,769 | D | ↗ |
| 2025-02-28 | Morrone Louis H. | Officer | F-InKind | D | Common shares without par value | 4,386 | 135.87 | 595.9K | 67,989 | D | ↗ |
| 2025-02-28 | Moreland Mary K | Officer | F-InKind | D | Common shares without par value | 5,598 | 135.87 | 760.6K | 96,374 | D | ↗ |
| 2025-02-28 | MCCOY JOHN A. JR. | Officer | F-InKind | D | Common shares without par value | 1,096 | 135.87 | 148.9K | 21,623 | D | ↗ |
| 2025-02-28 | Ford Robert B | Director / Officer | F-InKind | D | Common shares without par value | 31,651 | 135.87 | 4.30M | 253,305 | D | ↗ |
| 2025-02-28 | Earnhardt Lisa D | Officer | F-InKind | D | Common shares without par value | 8,322 | 135.87 | 1.13M | 71,928 | D | ↗ |
| 2025-02-28 | Boudreau Philip P | Officer | F-InKind | D | Common shares without par value | 4,908 | 135.87 | 666.8K | 56,553 | D | ↗ |
| 2025-02-28 | ALLEN HUBERT L | Officer | F-InKind | D | Common shares without par value | 8,382 | 135.87 | 1.14M | 191,899 | D | ↗ |
| 2025-02-25 | Wainer Andrea F | Officer | A-Award | A | Option (right to buy) | 45,730 | 135.42 | 6.19M | 45,730 | D | ↗ |
| 2025-02-25 | Salvadori Daniel Gesua Sive | Officer | A-Award | A | Common shares without par value | 16,534 | 0.00 | — | 142,231 | D | ↗ |
| 2025-02-25 | Morrone Louis H. | Officer | A-Award | A | Option (right to buy) | 38,108 | 135.42 | 5.16M | 38,108 | D | ↗ |
| 2025-02-25 | Moreland Mary K | Officer | A-Award | A | Option (right to buy) | 39,896 | 135.42 | 5.40M | 39,896 | D | ↗ |
| 2025-02-25 | MCCOY JOHN A. JR. | Officer | A-Award | A | Option (right to buy) | 15,040 | 135.42 | 2.04M | 15,040 | D | ↗ |
| 2025-02-25 | Ford Robert B | Director / Officer | A-Award | A | Common shares without par value | 64,897 | 0.00 | — | 284,956 | D | ↗ |
| 2025-02-25 | Earnhardt Lisa D | Officer | A-Award | A | Common shares without par value | 18,788 | 0.00 | — | 80,250 | D | ↗ |
| 2025-02-25 | Boudreau Philip P | Officer | A-Award | A | Option (right to buy) | 83,783 | 135.42 | 11.35M | 83,783 | D | ↗ |
| 2025-02-25 | ALLEN HUBERT L | Officer | A-Award | A | Common shares without par value | 15,475 | 0.00 | — | 200,281 | D | ↗ |
| 2025-02-18 | Shroff Eric | Officer | — | — | Option (right to buy) | 20,404 | 117.58 | 2.40M | 0 | D | ↗ |
| 2025-02-05 | Ford Robert B | Director / Officer | M-Exempt | D | Option (right to buy) | 285,388 | 38.40 | 10.96M | 0 | D | ↗ |
| 2025-01-30 | Salvadori Daniel Gesua Sive | Officer | M-Exempt | D | Option (right to buy) | 23,771 | 38.40 | 912.8K | 0 | D | ↗ |
| 2025-01-30 | ALLEN HUBERT L | Officer | M-Exempt | D | Option (right to buy) | 58,428 | 38.40 | 2.24M | 0 | D | ↗ |
| 2025-01-29 | ALLEN HUBERT L | Officer | S-Sale | D | Common shares without par value | 131,360 | 128.35 | 16.86M | 184,806 | D | ↗ |
| 2025-01-28 | Morrone Louis H. | Officer | S-Sale | D | Common shares without par value | 2,644 | 127.39 | 336.8K | 0 | I | ↗ |
| 2024-12-31 | Stratton John G | Director | A-Award | A | Stock Equivalent Units | 324 | 0.00 | — | 11,650 | D | ↗ |
| 2024-12-31 | Roman Michael F | Director | A-Award | A | Stock Equivalent Units | 311 | 0.00 | — | 4,670 | D | ↗ |
| 2024-12-31 | Gonzalez Patricia Paola | Director | A-Award | A | Stock Equivalent Units | 291 | 0.00 | — | 4,125 | D | ↗ |
| 2024-12-31 | Alpern Robert J | Director | A-Award | A | Stock Equivalent Units | 69 | 0.00 | — | 9,988 | D | ↗ |
| 2024-10-21 | ALLEN HUBERT L | Officer | M-Exempt | A | Common shares without par value | 157,421 | 47.00 | 7.40M | 342,227 | D | ↗ |
| 2024-09-30 | Stratton John G | Director | A-Award | A | Stock Equivalent Units | 322 | 0.00 | — | 11,271 | D | ↗ |
| 2024-09-30 | Roman Michael F | Director | A-Award | A | Stock Equivalent Units | 309 | 0.00 | — | 4,338 | D | ↗ |
| 2024-09-30 | Gonzalez Patricia Paola | Director | A-Award | A | Stock Equivalent Units | 289 | 0.00 | — | 3,815 | D | ↗ |
| 2024-09-30 | Alpern Robert J | Director | A-Award | A | Stock Equivalent Units | 69 | 0.00 | — | 9,872 | D | ↗ |
| 2024-09-12 | Ford Robert B | Director / Officer | M-Exempt | A | Common shares without par value | 14,243 | 48.90 | 696.5K | 361,738 | — | ↗ |
| 2024-09-04 | MCCOY JOHN A. JR. | Officer | S-Sale | D | Common shares without par value | 27 | 114.83 | 3.1K | 18,681 | — | ↗ |
| 2024-09-01 | MCCOY JOHN A. JR. | Officer | F-InKind | D | Common shares without par value | 52 | 113.27 | 5.9K | 18,708 | — | ↗ |
| 2024-09-01 | Boudreau Philip P | Officer | F-InKind | D | Common shares without par value | 387 | 113.27 | 43.8K | 38,966 | — | ↗ |
| 2024-07-01 | Morrone Louis H. | Officer | F-InKind | D | Common shares without par value | 556 | 103.91 | 57.8K | 62,143 | — | ↗ |
| 2024-06-30 | Stratton John G | Director | A-Award | A | Stock Equivalent Units | 353 | 0.00 | — | 10,895 | — | ↗ |
| 2024-06-30 | Roman Michael F | Director | A-Award | A | Stock Equivalent Units | 339 | 0.00 | — | 4,009 | — | ↗ |
| 2024-06-30 | Morrone Louis H. | Officer | F-InKind | D | Common shares without par value | 269 | 103.91 | 28.0K | 62,699 | — | ↗ |
| 2024-06-30 | Gonzalez Patricia Paola | Director | A-Award | A | Stock Equivalent Units | 317 | 0.00 | — | 3,509 | — | ↗ |
| 2024-06-30 | Alpern Robert J | Director | A-Award | A | Stock Equivalent Units | 75 | 0.00 | — | 9,754 | — | ↗ |
| 2024-05-10 | Funck, Jr. Robert E. | Officer | M-Exempt | D | Option (right to buy) | 10,097 | 47.00 | 474.6K | 45,000 | — | ↗ |
| 2024-05-07 | Earnhardt Lisa D | Officer | S-Sale | D | Common shares without par value | 22,852 | 106.25 | 2.43M | 61,462 | — | ↗ |
| 2024-04-26 | Stratton John G | Director | A-Award | A | Common shares without par value | 1,866 | 0.00 | — | 17,398 | — | ↗ |
| 2024-04-26 | STARKS DANIEL J | Director | A-Award | A | Option (right to buy) | 5,277 | 107.14 | 565.4K | 5,277 | — | ↗ |
| 2024-04-26 | Roman Michael F | Director | A-Award | A | Common shares without par value | 1,866 | 0.00 | — | 6,843 | — | ↗ |
| 2024-04-26 | O'Grady Michael | Director | A-Award | A | Option (right to buy) | 4,404 | 107.14 | 471.8K | 4,404 | — | ↗ |
| 2024-04-26 | McKinstry Nancy | Director | A-Award | A | Option (right to buy) | 6,850 | 107.14 | 733.9K | 6,850 | — | ↗ |
| 2024-04-26 | McDew Darren W | Director | A-Award | A | Common shares without par value | 1,866 | 0.00 | — | 8,757 | — | ↗ |
| 2024-04-26 | Kumbier Michelle | Director | A-Award | A | Common shares without par value | 1,866 | 0.00 | — | 14,079 | — | ↗ |
| 2024-04-26 | Gonzalez Patricia Paola | Director | A-Award | A | Common shares without par value | 1,866 | 0.00 | — | 5,284 | — | ↗ |
| 2024-04-26 | Blount Sally E. | Director | A-Award | A | Common shares without par value | 1,866 | 0.00 | — | 35,023 | — | ↗ |
| 2024-04-26 | Babineaux-Fontenot Claire | Director | A-Award | A | Common shares without par value | 1,866 | 0.00 | — | 3,682 | — | ↗ |
| 2024-04-26 | Alpern Robert J | Director | A-Award | A | Common shares without par value | 1,866 | 0.00 | — | 39,163 | — | ↗ |
| 2024-03-31 | Stratton John G | Director | A-Award | A | Stock Equivalent Units | 323 | 0.00 | — | 10,486 | — | ↗ |
| 2024-03-31 | Roman Michael F | Director | A-Award | A | Stock Equivalent Units | 310 | 0.00 | — | 3,650 | — | ↗ |
| 2024-03-31 | Gonzalez Patricia Paola | Director | A-Award | A | Stock Equivalent Units | 290 | 0.00 | — | 3,174 | — | ↗ |
| 2024-03-31 | Alpern Robert J | Director | A-Award | A | Stock Equivalent Units | 69 | 0.00 | — | 9,628 | — | ↗ |
| 2024-03-01 | Salvadori Daniel Gesua Sive | Officer | S-Sale | D | Common shares without par value | 963 | 118.50 | 114.1K | 125,697 | — | ↗ |
| 2024-03-01 | Morrone Louis H. | Officer | S-Sale | D | Common shares without par value | 801 | 118.50 | 94.9K | 62,968 | — | ↗ |
| 2024-03-01 | Moreland Mary K | Officer | S-Sale | D | Common shares without par value | 676 | 118.50 | 80.1K | 91,260 | — | ↗ |
| 2024-03-01 | MCCOY JOHN A. JR. | Officer | S-Sale | D | Common shares without par value | 472 | 118.50 | 55.9K | 18,760 | — | ↗ |
| 2024-03-01 | Earnhardt Lisa D | Officer | S-Sale | D | Common shares without par value | 694 | 118.50 | 82.2K | 84,314 | — | ↗ |
| 2024-03-01 | ALLEN HUBERT L | Officer | S-Sale | D | Common shares without par value | 853 | 118.50 | 101.1K | 184,806 | — | ↗ |
| 2024-02-29 | Wainer Andrea F | Officer | F-InKind | D | Common shares without par value | 8,339 | 120.05 | 1.00M | 70,365 | — | ↗ |
| 2024-02-29 | Salvadori Daniel Gesua Sive | Officer | F-InKind | D | Common shares without par value | 8,874 | 120.05 | 1.07M | 126,660 | — | ↗ |
| 2024-02-29 | Morrone Louis H. | Officer | F-InKind | D | Common shares without par value | 3,455 | 120.05 | 414.8K | 63,769 | — | ↗ |
| 2024-02-29 | Moreland Mary K | Officer | F-InKind | D | Common shares without par value | 5,862 | 120.05 | 703.7K | 91,936 | — | ↗ |
| 2024-02-29 | MCCOY JOHN A. JR. | Officer | F-InKind | D | Common shares without par value | 921 | 120.05 | 110.6K | 19,232 | — | ↗ |
| 2024-02-29 | Funck, Jr. Robert E. | Officer | F-InKind | D | Common shares without par value | 11,415 | 120.05 | 1.37M | 211,341 | — | ↗ |
| 2024-02-29 | Ford Robert B | Director / Officer | F-InKind | D | Common shares without par value | 31,610 | 120.05 | 3.79M | 220,059 | — | ↗ |
| 2024-02-29 | Earnhardt Lisa D | Officer | F-InKind | D | Common shares without par value | 7,669 | 120.05 | 920.7K | 85,008 | — | ↗ |
| 2024-02-29 | Boudreau Philip P | Officer | F-InKind | D | Common shares without par value | 1,738 | 120.05 | 208.6K | 39,353 | — | ↗ |
| 2024-02-29 | ALLEN HUBERT L | Officer | F-InKind | D | Common shares without par value | 8,214 | 120.05 | 986.1K | 185,659 | — | ↗ |
| 2024-02-23 | Wainer Andrea F | Officer | M-Exempt | A | Common shares without par value | 12,500 | 59.94 | 749.3K | 91,204 | — | ↗ |
| 2024-02-21 | Wainer Andrea F | Officer | A-Award | A | Option (right to buy) | 51,397 | 116.98 | 6.01M | 51,397 | — | ↗ |
| 2024-02-21 | Salvadori Daniel Gesua Sive | Officer | A-Award | A | Option (right to buy) | 58,898 | 116.98 | 6.89M | 58,898 | — | ↗ |
| 2024-02-21 | Morrone Louis H. | Officer | A-Award | A | Option (right to buy) | 46,257 | 116.98 | 5.41M | 46,257 | — | ↗ |
| 2024-02-21 | Moreland Mary K | Officer | A-Award | A | Option (right to buy) | 39,734 | 116.98 | 4.65M | 39,734 | — | ↗ |
| 2024-02-21 | MCCOY JOHN A. JR. | Officer | A-Award | A | Common shares without par value | 4,407 | 0.00 | — | 20,153 | — | ↗ |
| 2024-02-21 | Funck, Jr. Robert E. | Officer | A-Award | A | Option (right to buy) | 92,137 | 116.98 | 10.78M | 92,137 | — | ↗ |
| 2024-02-21 | Ford Robert B | Director / Officer | A-Award | A | Common shares without par value | 70,332 | 0.00 | — | 251,669 | — | ↗ |
| 2024-02-21 | Earnhardt Lisa D | Officer | A-Award | A | Option (right to buy) | 64,787 | 116.98 | 7.58M | 64,787 | — | ↗ |
| 2024-02-21 | Boudreau Philip P | Officer | A-Award | A | Option (right to buy) | 86,519 | 116.98 | 10.12M | 86,519 | — | ↗ |
| 2024-02-21 | ALLEN HUBERT L | Officer | A-Award | A | Common shares without par value | 17,914 | 0.00 | — | 193,873 | — | ↗ |
| 2024-02-19 | Shroff Eric | Officer | — | — | Option (right to buy) | 20,045 | 124.04 | 2.49M | 0 | D | ↗ |
| 2024-02-17 | MCCOY JOHN A. JR. | Officer | — | D | Option (right to buy) | 12,759 | 106.24 | 1.36M | 0 | — | ↗ |
| 2024-01-29 | Wainer Andrea F | Officer | M-Exempt | A | Common shares without par value | 25,000 | 44.40 | 1.11M | 90,027 | — | ↗ |
| 2023-12-31 | Stratton John G | Director | A-Award | A | Stock Equivalent Units | 333 | 0.00 | — | 10,114 | — | ↗ |
| 2023-12-31 | Roman Michael F | Director | A-Award | A | Stock Equivalent Units | 320 | 0.00 | — | 3,324 | — | ↗ |
| 2023-12-31 | Gonzalez Patricia Paola | Director | A-Award | A | Stock Equivalent Units | 299 | 0.00 | — | 2,870 | — | ↗ |
| 2023-12-31 | Alpern Robert J | Director | A-Award | A | Stock Equivalent Units | 71 | 0.00 | — | 9,512 | — | ↗ |
| 2023-12-14 | Wainer Andrea F | Officer | S-Sale | D | Common shares without par value | 15,000 | 108.00 | 1.62M | 65,027 | — | ↗ |
| 2023-10-26 | STARKS DANIEL J | Director | S-Sale | D | Common shares without par value | 26,907 | 93.81 | 2.52M | 6,748,409 | — | ↗ |
| 2023-09-30 | Stratton John G | Director | A-Award | A | Stock Equivalent Units | 379 | 0.00 | — | 9,729 | — | ↗ |
| 2023-09-30 | Roman Michael F | Director | A-Award | A | Stock Equivalent Units | 363 | 0.00 | — | 2,988 | — | ↗ |
| 2023-09-30 | Gonzalez Patricia Paola | Director | A-Award | A | Stock Equivalent Units | 340 | 0.00 | — | 2,557 | — | ↗ |
| 2023-09-30 | Alpern Robert J | Director | A-Award | A | Stock Equivalent Units | 81 | 0.00 | — | 9,392 | — | ↗ |
| 2023-09-13 | Funck, Jr. Robert E. | Officer | G-Gift | D | Common shares without par value | 20,000 | 0.00 | — | 198,237 | — | ↗ |
| 2023-09-01 | MCCOY JOHN A. JR. | Officer | A-Award | A | Common shares without par value | 531 | 0.00 | — | 15,746 | — | ↗ |
| 2023-09-01 | Boudreau Philip P | Officer | A-Award | A | Common shares without par value | 2,620 | 0.00 | — | 18,067 | — | ↗ |
| 2023-08-08 | Wainer Andrea F | Officer | S-Sale | D | Common shares without par value | 272 | 105.43 | 28.7K | 65,043 | — | ↗ |
| 2023-07-27 | STARKS DANIEL J | Director | S-Sale | D | Common shares without par value | 20,934 | 113.43 | 2.37M | 6,804,382 | — | ↗ |
| 2023-07-01 | Morrone Louis H. | Officer | F-InKind | D | Common shares without par value | 556 | 109.02 | 60.6K | 54,915 | — | ↗ |
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Robert B. Ford , Chairman of the Board and Chief Executive Officer | 1.50M | — | 8.79M | 8.79M | 1.97M | 3.15M | 24.20M | 72.63% | ↗ |
| 2 | 2025 | Philip P. Boudreau , Executive Vice President, Finance and Chief Financial Officer | 974.2K | — | 3.05M | 3.05M | 1.06M | 968.7K | 9.09M | 67.02% | ↗ |
| 3 | 2025 | Lisa D. Earnhardt , Executive Vice President and Group President, Medical Devices | 924.2K | — | 2.54M | 2.54M | 1.28M | 773.7K | 8.07M | 63.05% | ↗ |
| 4 | 2025 | Hubert L. Allen , Former Executive Vice President, General Counsel and Secretary | 524.0K | — | 2.10M | 2.10M | 447.5K | 1.83M | 7.00M | 59.91% | ↗ |
| 5 | 2025 | Christopher J. Scoggins , Executive Vice President, Diabetes Care | 859.5K | — | 1.66M | 1.66M | 1.10M | 1.32M | 6.60M | 50.37% | ↗ |
| 6 | 2025 | Daniel G. Salvadori , Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | 924.2K | — | 2.24M | 2.24M | 388.2K | 744.0K | 6.53M | 68.53% | ↗ |
| 7 | 2024 | Robert B. Ford , Chairman of the Board and Chief Executive Officer | 1.50M | — | 8.23M | 8.23M | 2.86M | 1.96M | 22.78M | 72.24% | ↗ |
| 8 | 2024 | Robert B. Ford, Chairman of the Board and Chief Executive Officer | 1.50M | — | 8.23M | 8.23M | 2.86M | 1.96M | 22.78M | 72.24% | ↗ |
| 9 | 2024 | Robert E. Funck, Jr. Former Executive Vice President, Finance | 535.1K | — | 2.87M | 2.87M | 564.0K | 1.42M | 8.26M | 69.46% | ↗ |
| 10 | 2024 | Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer | 884.0K | — | 2.69M | 2.69M | 1.22M | 730.6K | 8.23M | 65.48% | ↗ |
| 11 | 2024 | Philip P. Boudreau , Executive Vice President, Finance and Chief Financial Officer | 884.0K | — | 2.69M | 2.69M | 1.22M | 730.6K | 8.23M | 65.48% | ↗ |
| 12 | 2024 | Hubert L. Allen , Former Executive Vice President, General Counsel and Secretary | 911.2K | — | 2.10M | 2.10M | 1.09M | 1.78M | 7.98M | 52.51% | ↗ |
| 13 | 2024 | Hubert L. Allen, Executive Vice President, General Counsel and Secretary | 911.2K | — | 2.10M | 2.10M | 1.09M | 1.78M | 7.98M | 52.51% | ↗ |
| 14 | 2024 | Lisa D. Earnhardt , Executive Vice President and Group President, Medical Devices | 879.3K | — | 2.02M | 2.02M | 1.25M | 396.6K | 6.56M | 61.50% | ↗ |
| 15 | 2024 | Lisa D. Earnhardt, Executive Vice President and Group President, Medical Devices | 879.3K | — | 2.02M | 2.02M | 1.25M | 396.6K | 6.56M | 61.50% | ↗ |
| 16 | 2024 | Daniel G. Salvadori , Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | 879.3K | — | 1.83M | 1.83M | 855.4K | 388.4K | 5.79M | 63.33% | ↗ |
| 17 | 2024 | Daniel G. Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | 879.3K | — | 1.83M | 1.83M | 855.4K | 388.4K | 5.79M | 63.33% | ↗ |
| 18 | 2023 | Robert B. Ford, Chairman of the Board and Chief Executive Officer | 1.50M | — | 7.44M | 7.44M | 2.95M | 3.95M | 23.27M | 63.93% | ↗ |
| 19 | 2023 | Robert B. Ford , Chairman of the Board and Chief Executive Officer | 1.50M | — | 7.44M | 7.44M | 2.95M | 3.95M | 23.27M | 63.93% | ↗ |
| 20 | 2023 | Robert E. Funck, Jr., Executive Vice President, Finance | 875.0K | — | 2.59M | 2.59M | 1.06M | 1.87M | 8.99M | 57.70% | ↗ |
| 21 | 2023 | Robert E. Funck, Jr. Former Executive Vice President, Finance | 875.0K | — | 2.59M | 2.59M | 1.06M | 1.87M | 8.99M | 57.70% | ↗ |
| 22 | 2023 | Hubert L. Allen , Former Executive Vice President, General Counsel and Secretary | 830.0K | — | 1.96M | 1.96M | 941.7K | 1.73M | 7.42M | 52.82% | ↗ |
| 23 | 2023 | Hubert L. Allen, Executive Vice President, General Counsel and Secretary | 830.0K | — | 1.96M | 1.96M | 941.7K | 1.73M | 7.42M | 52.82% | ↗ |
| 24 | 2023 | Daniel G. Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | 790.0K | — | 1.88M | 1.88M | 880.3K | 503.9K | 5.93M | 63.37% | ↗ |
| 25 | 2023 | Daniel G. Salvadori , Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | 790.0K | — | 1.88M | 1.88M | 880.3K | 503.9K | 5.93M | 63.37% | ↗ |
| 26 | 2023 | Lisa D. Earnhardt , Executive Vice President and Group President, Medical Devices | 737.7K | — | 1.68M | 1.68M | 904.9K | 487.2K | 5.50M | 61.27% | ↗ |
| 27 | 2023 | Lisa D. Earnhardt, Executive Vice President and Group President, Medical Devices | 737.7K | — | 1.68M | 1.68M | 904.9K | 487.2K | 5.50M | 61.27% | ↗ |
| 28 | 2023 | Philip P. Boudreau, Senior Vice President, Finance and Chief Financial Officer | 513.9K | — | 786.0K | 786.3K | 583.5K | 647.4K | 3.32M | 47.40% | ↗ |
| 29 | 2023 | Philip P. Boudreau , Executive Vice President, Finance and Chief Financial Officer | 513.9K | — | 786.0K | 786.3K | 583.5K | 647.4K | 3.32M | 47.40% | ↗ |
| 30 | 2023 | Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer | 513.9K | — | 786.0K | 786.3K | 583.5K | 647.4K | 3.32M | 47.40% | ↗ |
| 31 | 2022 | Robert B. Ford, Chairman of the Board and Chief Executive Officer | 1.50M | — | 8.70M | 8.70M | 2.23M | 591.3K | 21.72M | 80.10% | ↗ |
| 32 | 2022 | Robert E. Funck, Jr., Executive Vice President, Finance | 866.2K | — | 3.37M | 3.37M | 956.0K | 578.3K | 9.15M | 73.75% | ↗ |
| 33 | 2022 | Robert E. Funck, Jr. Former Executive Vice President, Finance | 866.2K | — | 3.37M | 3.37M | 956.0K | 578.3K | 9.15M | 73.75% | ↗ |
| 34 | 2022 | Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer | 866.2K | — | 3.37M | 3.37M | 956.0K | 578.3K | 9.15M | 73.75% | ↗ |
| 35 | 2022 | Daniel G. Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | 790.0K | — | 2.81M | 2.81M | 600.5K | 142.4K | 7.16M | 78.58% | ↗ |
| 36 | 2022 | Hubert L. Allen, Executive Vice President, General Counsel and Secretary | 817.6K | — | 2.40M | 2.40M | 871.5K | 536.9K | 7.02M | 68.29% | ↗ |
| 37 | 2022 | Andrea F. Wainer, Executive Vice President, Rapid and Molecular Diagnostics | 710.0K | — | 2.23M | 2.23M | 906.3K | 209.4K | 6.29M | 70.96% | ↗ |
| 38 | 2021 | Robert B. Ford, Chairman of the Board and Chief Executive Officer | 1.48M | — | 8.69M | 8.69M | 3.17M | 2.88M | 24.91M | 69.75% | ↗ |
| 39 | 2021 | Miles D. White, Former Executive Chairman of the Board | 1.90M | — | 5.50M | 5.50M | — | 3.05M | 15.95M | 68.95% | ↗ |
| 40 | 2021 | Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer | 825.0K | — | 3.00M | 3.00M | 1.05M | 1.67M | 9.54M | 62.89% | ↗ |
| 41 | 2021 | Robert E. Funck, Jr., Executive Vice President, Finance | 825.0K | — | 3.00M | 3.00M | 1.05M | 1.67M | 9.54M | 62.89% | ↗ |
| 42 | 2021 | Andrea F. Wainer, Executive Vice President, Rapid and Molecular Diagnostics | 699.6K | — | 2.39M | 2.39M | 931.6K | 842.0K | 7.25M | 65.89% | ↗ |
| 43 | 2021 | Hubert L. Allen, Executive Vice President, General Counsel and Secretary | 760.0K | — | 2.12M | 2.12M | 921.7K | 941.1K | 6.85M | 61.73% | ↗ |
| 44 | 2021 | Daniel G. Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | 715.5K | — | 2.39M | 2.39M | 925.7K | 323.9K | 6.74M | 70.85% | ↗ |
| 45 | 2020 | Robert B. Ford, Chairman of the Board and Chief Executive Officer | 1.30M | — | 5.62M | 5.62M | 3.68M | 4.23M | 20.45M | 55.01% | ↗ |
| 46 | 2020 | Robert B. Ford, President and Chief Executive Officer, and Director | 1.30M | — | 5.62M | 5.62M | 3.68M | 77.9K | 20.45M | 55.01% | ↗ |
| 47 | 2020 | Miles D. White, Former Executive Chairman of the Board | 1.90M | — | 6.00M | 6.00M | 1.25M | 4.68M | 19.83M | 60.51% | ↗ |
| 48 | 2020 | Miles D. White, Executive Chairman of the Board | 1.90M | — | 6.00M | 6.00M | 1.25M | 1.26M | 19.83M | 60.51% | ↗ |
| 49 | 2020 | Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer | 813.5K | — | 2.22M | 2.22M | 1.28M | 3.27M | 9.80M | 45.22% | ↗ |
| 50 | 2020 | Hubert L. Allen, Executive Vice President, General Counsel and Secretary | 751.3K | — | 1.87M | 1.87M | 917.7K | 3.06M | 8.48M | 44.23% | ↗ |
| 51 | 2020 | John F. Ginascol, Executive Vice President, Core Diagnostics | 708.3K | — | 1.65M | 1.65M | 857.3K | 112.7K | 6.77M | 48.88% | ↗ |
| 52 | 2020 | Daniel G. Salvadori, Executive Vice President, Nutritional Products | 710.0K | — | 1.90M | 1.90M | 905.5K | 79.4K | 5.98M | 63.65% | ↗ |
| 53 | 2020 | Daniel G. Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | 710.0K | — | 1.90M | 1.90M | 905.5K | 556.4K | 5.98M | 63.65% | ↗ |
| 54 | 2020 | Brian B. Yoor, Former Executive Vice President, Finance and Chief Financial Officer | 207.8K | — | 1.23M | 1.23M | — | 38.3K | 3.49M | 70.56% | ↗ |
| 55 | 2019 | Miles D. White, Former Executive Chairman of the Board | 1.90M | — | 7.56M | 7.56M | 4.41M | 6.37M | 27.80M | 54.40% | ↗ |
| 56 | 2019 | Miles D. White, Executive Chairman of the Board | 1.90M | — | 7.56M | 7.56M | 4.41M | 664.4K | 27.80M | 54.40% | ↗ |
| 57 | 2019 | Miles D. White, Chairman of the Board, Chief Executive Officer, and Director | 1.90M | — | 7.56M | 7.56M | 4.41M | 664.4K | 27.80M | 54.40% | ↗ |
| 58 | 2019 | Robert B. Ford, President and Chief Executive Officer, and Director | 1.00M | — | 3.48M | 3.48M | 1.56M | 71.8K | 11.90M | 58.43% | ↗ |
| 59 | 2019 | Robert B. Ford, President and Chief Operating Officer, and Director | 1.00M | — | 3.48M | 3.48M | 1.56M | 71.8K | 11.90M | 58.43% | ↗ |
| 60 | 2019 | Robert B. Ford, Chairman of the Board and Chief Executive Officer | 1.00M | — | 3.48M | 3.48M | 1.56M | 2.38M | 11.90M | 58.43% | ↗ |
| 61 | 2019 | Brian B. Yoor, Executive Vice President, Finance and Chief Financial Officer | 825.0K | — | 2.45M | 2.45M | 1.11M | 71.3K | 9.02M | 54.35% | ↗ |
| 62 | 2019 | Brian B. Yoor, Former Executive Vice President, Finance and Chief Financial Officer | 825.0K | — | 2.45M | 2.45M | 1.11M | 71.3K | 9.02M | 54.35% | ↗ |
| 63 | 2019 | Hubert L. Allen, Executive Vice President, General Counsel and Secretary | 710.0K | — | 2.20M | 2.20M | 879.7K | 1.50M | 7.49M | 58.78% | ↗ |
| 64 | 2019 | Lisa D. Earnhardt, Executive Vice President, Medical Devices | 400.1K | — | 4.61M | 1.35M | 910.4K | 19.8K | 7.48M | 79.75% | ↗ |
| 65 | 2019 | Daniel G. Salvadori, Executive Vice President, Nutritional Products | 704.9K | — | 2.35M | 2.35M | 903.4K | 59.8K | 6.77M | 69.51% | ↗ |
| 66 | 2019 | Daniel G. Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | 704.9K | — | 2.35M | 2.35M | 903.4K | 455.5K | 6.77M | 69.51% | ↗ |
| 67 | 2018 | Miles D. White, Executive Chairman of the Board | 1.90M | — | 7.50M | 7.50M | 4.78M | 1.19M | 24.25M | 61.84% | ↗ |
| 68 | 2018 | Miles D. White, Chairman of the Board, Chief Executive Officer, and Director | 1.90M | — | 7.50M | 7.50M | 4.78M | 1.19M | 24.25M | 61.84% | ↗ |
| 69 | 2018 | Robert B. Ford, President and Chief Operating Officer | 784.3K | — | 2.69M | 2.69M | 1.30M | 279.2K | 8.13M | 66.24% | ↗ |
| 70 | 2018 | Robert B. Ford, President and Chief Executive Officer, and Director | 784.3K | — | 2.69M | 2.69M | 1.30M | 279.2K | 8.13M | 66.24% | ↗ |
| 71 | 2018 | Robert B. Ford, President and Chief Operating Officer, and Director | 784.3K | — | 2.69M | 2.69M | 1.30M | 279.2K | 8.13M | 66.24% | ↗ |
| 72 | 2018 | Brian B. Yoor, Executive Vice President, Finance and Chief Financial Officer | 796.1K | — | 2.69M | 2.69M | 974.6K | 73.5K | 7.61M | 70.72% | ↗ |
| 73 | 2018 | Brian B. Yoor, Former Executive Vice President, Finance and Chief Financial Officer | 796.1K | — | 2.69M | 2.69M | 974.6K | 73.5K | 7.61M | 70.72% | ↗ |
| 74 | 2018 | Hubert L. Allen, Executive Vice President, General Counsel and Secretary | 706.7K | — | 2.69M | 2.69M | 902.0K | 120.3K | 7.32M | 73.57% | ↗ |
| 75 | 2018 | Stephen R. Fussell, Executive Vice President, Human Resources | 620.0K | — | 2.69M | 2.69M | 682.0K | 97.8K | 6.84M | 78.72% | ↗ |
| 76 | 2018 | Daniel G. Salvadori, Executive Vice President, Nutritional Products | 675.0K | — | 1.99M | 1.99M | 803.2K | 434.5K | 5.95M | 66.97% | ↗ |
| 77 | 2017 | Miles D. White, Chairman of the Board, Chief Executive Officer and Director | 1.90M | — | 4.10M | 4.10M | 4.50M | 4.37M | 18.97M | 43.22% | ↗ |
| 78 | 2017 | Miles D. White, Chairman of the Board, Chief Executive Officer, and Director | 1.90M | — | 4.10M | 4.10M | 4.50M | 1.02M | 18.97M | 43.22% | ↗ |
| 79 | 2017 | Michael T. Rousseau , President, Cardiovascular and Neuromodulation | 644.2K | 5.00M | — | — | 643.8K | 12.52M | 18.81M | 0.00% | ↗ |
| 80 | 2017 | Eric S. Fain , Senior Vice President, Group President, Cardiovascular and Neuromodulation | 557.0K | — | 3.02M | 1.02M | 174.7K | 8.55M | 13.33M | 30.38% | ↗ |
| 81 | 2017 | Hubert L. Allen, Executive Vice President, General Counsel and Secretary | 690.1K | — | 1.07M | 1.07M | 1.02M | 71.1K | 4.87M | 44.06% | ↗ |
| 82 | 2017 | Robert B. Ford, Executive Vice President, Medical Devices | 675.0K | — | 974.9K | 975.0K | 1.07M | 1.01M | 4.70M | 41.47% | ↗ |
| 83 | 2017 | Robert B. Ford, President and Chief Operating Officer, and Director | 675.0K | — | 974.9K | 975.0K | 1.07M | 60.9K | 4.70M | 41.47% | ↗ |
| 84 | 2017 | Robert B. Ford, President and Chief Operating Officer | 675.0K | — | 974.9K | 975.0K | 1.07M | 60.9K | 4.70M | 41.47% | ↗ |
| 85 | 2017 | Brian B. Yoor, Executive Vice President, Finance and Chief Financial Officer | 643.3K | — | 877.4K | 877.5K | 1.06M | 63.0K | 4.54M | 38.68% | ↗ |
| 86 | 2017 | Daniel G. Salvadori, Executive Vice President, Nutritional Products | 608.5K | — | 1.25M | 1.26M | 733.7K | 54.6K | 4.09M | 61.45% | ↗ |
| 87 | 2016 | Miles D. White, Chairman of the Board, Chief Executive Officer, and Director | 1.90M | — | 5.25M | 5.25M | 3.20M | 825.6K | 20.29M | 51.76% | ↗ |
| 88 | 2016 | Miles D. White, Chairman of the Board, Chief Executive Officer and Director | 1.90M | — | 5.25M | 5.25M | 3.20M | 4.69M | 20.29M | 51.76% | ↗ |
| 89 | 2016 | Thomas C. Freyman , Executive Vice President, Finance and Administration | 999.4K | — | 2.12M | 2.12M | 1.35M | 404.9K | 7.00M | 60.70% | ↗ |
| 90 | 2016 | Michael J. Warmuth, Executive Vice President, Established | 691.9K | — | 1.37M | 1.37M | 730.0K | 1.19M | 5.36M | 51.31% | ↗ |
| 91 | 2016 | Brian J. Blaser, Executive Vice President, Diagnostic Products | 692.1K | — | 1.56M | 1.56M | 664.3K | 621.5K | 5.10M | 61.24% | ↗ |
| 92 | 2016 | Brian B. Yoor, Executive Vice President, Finance and Chief Financial Officer | 584.2K | — | 934.8K | 935.0K | 622.8K | 60.2K | 3.59M | 52.08% | ↗ |
| 93 | 2015 | Miles D. White, Chairman of the Board, Chief Executive Officer and Director | 1.90M | — | 6.25M | 6.25M | 3.30M | 1.70M | 19.40M | 64.42% | ↗ |
| 94 | 2015 | Thomas C. Freyman , Executive Vice President, Finance and Administration | 975.1K | — | 1.90M | 1.90M | 1.02M | 274.2K | 6.07M | 62.62% | ↗ |
| 95 | 2015 | Thomas C. Freyman, Executive Vice President, Finance and Administration | 975.1K | — | 1.90M | 1.90M | 1.02M | 274.2K | 6.07M | 62.62% | ↗ |
| 96 | 2015 | Michael J. Warmuth, Executive Vice President, Established | 675.0K | — | 1.21M | 1.21M | 700.0K | 981.7K | 4.77M | 50.61% | ↗ |
| 97 | 2015 | Brian J. Blaser, Executive Vice President, Diagnostic Products | 675.0K | — | 1.15M | 1.15M | 700.0K | 305.4K | 3.99M | 57.89% | ↗ |
| 98 | 2015 | John M. Capek, Executive Vice President, Ventures | 675.0K | — | 1.10M | 1.10M | 585.0K | 301.3K | 3.77M | 58.54% | ↗ |
| 99 | 2015 | Brian B. Yoor, Senior Vice President, Finance and Chief Financial Officer | 437.9K | — | 841.8K | 833.1K | 427.5K | 172.4K | 2.71M | 61.74% | ↗ |
| 100 | 2015 | Brian B. Yoor, Executive Vice President, Finance and Chief Financial Officer | 437.9K | — | 841.8K | 833.1K | 427.5K | 172.4K | 2.71M | 61.74% | ↗ |
| 101 | 2014 | Miles D. White, Chairman of the Board, Chief Executive Officer and Director | 1.97M | — | 4.65M | 4.65M | 3.80M | 2.66M | 17.73M | 52.45% | ↗ |
| 102 | 2014 | Thomas C. Freyman , Executive Vice President, Finance and Administration | 1.01M | — | 1.28M | 1.28M | 1.20M | 2.53M | 7.31M | 35.06% | ↗ |
| 103 | 2014 | Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer | 1.01M | — | 1.28M | 1.28M | 1.20M | 2.53M | 7.31M | 35.06% | ↗ |
| 104 | 2014 | Thomas C. Freyman, Executive Vice President, Finance and Administration | 1.01M | — | 1.28M | 1.28M | 1.20M | 2.53M | 7.31M | 35.06% | ↗ |
| 105 | 2014 | John C. Landgraf, Executive Vice President, Nutrition Products | 743.3K | — | 990.1K | 990.2K | 401.6K | 1.53M | 4.66M | 42.53% | ↗ |
| 106 | 2014 | Brian J. Blaser, Executive Vice President, Diagnostic Products | 690.0K | — | 1.12M | 1.12M | 668.0K | 653.7K | 4.25M | 52.67% | ↗ |
| 107 | 2014 | John M. Capek, Executive Vice President, Ventures | 696.8K | — | 904.0K | 904.0K | 653.8K | 640.7K | 3.80M | 47.59% | ↗ |
| 108 | 2014 | John M. Capek, Executive Vice President, Medical Devices | 696.8K | — | 904.0K | 904.0K | 653.8K | 640.7K | 3.80M | 47.59% | ↗ |
| 109 | 2013 | Miles D. White, Chairman of the Board, Chief Executive Officer and Director | 1.90M | — | 7.34M | 7.06M | 3.15M | 1.42M | 20.87M | 69.01% | ↗ |
| 110 | 2013 | Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer | 969.7K | — | 2.01M | 1.78M | 912.0K | 206.6K | 5.88M | 64.49% | ↗ |
| 111 | 2013 | Thomas C. Freyman, Executive Vice President, Finance and Administration | 969.7K | — | 2.01M | 1.78M | 912.0K | 206.6K | 5.88M | 64.49% | ↗ |
| 112 | 2013 | Hubert L. Allen, Executive Vice President, General Counsel and Secretary | 650.0K | — | 1.11M | 952.1K | 682.5K | 380.7K | 3.77M | 54.59% | ↗ |
| 113 | 2013 | Richard W. Ashley, Executive Vice President, Corporate Development | 629.5K | — | 2.22M | — | 590.0K | 205.9K | 3.64M | 60.85% | ↗ |
| 114 | 2013 | Brian J. Blaser, Executive Vice President, Diagnostic Products | 614.6K | — | 1.11M | 952.1K | 800.0K | 105.3K | 3.58M | 57.54% | ↗ |
| 115 | 2013 | Brian J. Blaser, Executive Vice President, Diagnostics Products | 614.6K | — | 1.11M | 952.1K | 800.0K | 105.3K | 3.58M | 57.54% | ↗ |
| 116 | 2012 | Miles D. White, Chairman of the Board, Chief Executive Officer and Director | 1.90M | — | 9.43M | 2.06M | 4.70M | 7.03M | 25.12M | 45.73% | ↗ |
| 117 | 2012 | Laura J. Schumacher Executive Vice President, General Counsel and Secretary | 831.7K | 1.10M | 4.49M | 576.8K | 1.27M | 1.93M | 10.19M | 49.68% | ↗ |
| 118 | 2012 | Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer | 946.7K | 1.20M | 3.34M | 729.6K | 1.27M | 2.18M | 9.66M | 42.13% | ↗ |
| 119 | 2012 | Richard A. Gonzalez Executive Vice President, Pharmaceutical Products Group | 863.9K | — | 3.34M | 729.6K | 2.50M | 513.8K | 7.95M | 51.22% | ↗ |
| 120 | 2012 | Carlos Alban Senior Vice President, Proprietary Pharmaceuticals, Global Commercial Operations | 615.8K | 300.0K | 2.70M | 331.5K | 675.0K | 1.91M | 6.53M | 46.46% | ↗ |
| 121 | 2011 | Miles D. White, Chairman of the Board, Chief Executive Officer and Director | 1.90M | — | 9.76M | 1.84M | 4.20M | 6.32M | 24.01M | 48.29% | ↗ |
| 122 | 2011 | Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer | 946.7K | — | 2.86M | 537.6K | 1.27M | 2.34M | 7.95M | 42.70% | ↗ |
| 123 | 2011 | Laura J. Schumacher Executive Vice President, General Counsel and Secretary | 827.5K | — | 1.91M | 358.2K | 1.18M | 1.30M | 5.57M | 40.66% | ↗ |
| 124 | 2011 | Richard A. Gonzalez Executive Vice President, Pharmaceutical Products Group | 825.0K | — | 1.83M | 343.3K | 1.23M | 1.33M | 5.55M | 39.07% | ↗ |
| 125 | 2011 | Edward L. Michael Executive Vice President, Diagnostic Products | 634.4K | — | 1.83M | 499.4K | 750.0K | 1.62M | 5.33M | 43.67% | ↗ |
| 126 | 2010 | Miles D. White, Chairman of the Board, Chief Executive Officer and Director | 1.89M | — | 10.90M | 2.73M | 3.70M | 6.35M | 25.56M | 53.29% | ↗ |
| 127 | 2010 | James V. Mazzo, Senior Vice President, Abbott Medical Optics | 814.6K | — | 2.21M | 265.2K | 398.4K | 7.81M | 11.51M | 21.53% | ↗ |
| 128 | 2010 | Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer | 941.9K | — | 4.98M | 804.8K | 1.20M | 1.64M | 9.57M | 60.46% | ↗ |
| 129 | 2010 | Richard A. Gonzalez Executive Vice President, Pharmaceutical Products Group | 742.1K | 300.0K | 5.14M | — | 848.9K | 574.3K | 7.60M | 67.56% | ↗ |
| 130 | 2010 | Laura J. Schumacher Executive Vice President, General Counsel and Secretary | 823.3K | — | 3.90M | 535.9K | 1.10M | 766.8K | 7.13M | 62.26% | ↗ |
| 131 | 2009 | Miles D. White, Chairman of the Board, Chief Executive Officer and Director | 1.85M | — | 12.45M | 3.02M | 3.90M | 5.00M | 26.21M | 59.00% | ↗ |
| 132 | 2009 | James V. Mazzo, Senior Vice President, Abbott Medical Optics | 640.9K | — | 2.62M | — | 349.0K | 6.79M | 10.39M | 25.17% | ↗ |
| 133 | 2009 | Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer | 914.5K | — | 4.12M | 1.00M | 1.29M | 2.23M | 9.56M | 53.64% | ↗ |
| 134 | 2009 | Laura J. Schumacher Executive Vice President, General Counsel and Secretary | 799.4K | — | 2.48M | 602.3K | 1.08M | 768.3K | 5.72M | 53.83% | ↗ |
| 135 | 2009 | Laura J. Schumacher, Executive Vice President, General Counsel and Secretary | 799.4K | — | 2.48M | 602.3K | 1.08M | 768.3K | 5.72M | 53.83% | ↗ |
| 136 | 2009 | Olivier Bohuon, Executive Vice President, Abbott Pharmaceutical Products Group | 772.4K | — | 2.39M | 572.5K | 730.0K | 767.7K | 5.23M | 56.62% | ↗ |
| 137 | 2008 | Miles D. White, Chairman of the Board, Chief Executive Officer and Director | 1.80M | — | 7.50M | 10.76M | 4.20M | 4.00M | 28.25M | 64.62% | ↗ |
| 138 | 2008 | Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer | 886.4K | — | 1.74M | 1.46M | 1.23M | 1.15M | 6.47M | 49.48% | ↗ |
| 139 | 2008 | James L. Tyree, Executive Vice President, Pharmaceutical Products | 697.3K | — | 2.24M | 1.67M | 792.6K | 835.9K | 6.23M | 62.68% | ↗ |
| 140 | 2008 | John M. Capek, Executive Vice President, Medical Devices | 679.4K | — | 1.73M | 1.14M | 678.2K | 1.12M | 5.34M | 53.64% | ↗ |
| 141 | 2008 | Laura J. Schumacher Executive Vice President, General Counsel and Secretary | 774.8K | — | 1.51M | 1.50M | 986.7K | 487.5K | 5.26M | 57.20% | ↗ |
| 142 | 2008 | Laura J. Schumacher, Executive Vice President, General Counsel and Secretary | 774.8K | — | 1.51M | 1.50M | 986.7K | 487.5K | 5.26M | 57.20% | ↗ |
| 143 | 2007 | Miles D. White, Chairman of the Board, Chief Executive Officer and Director | 1.73M | — | 7.36M | 14.77M | 4.05M | 4.05M | 31.95M | 69.25% | ↗ |
| 144 | 2007 | Richard A. Gonzalez, Former Chief Operating Officer and Director | 951.8K | — | 7.64M | 5.91M | 1.29M | 1.37M | 17.15M | 78.96% | ↗ |
| 145 | 2007 | Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer | 852.5K | — | 2.55M | 3.53M | 1.20M | 1.19M | 9.33M | 65.20% | ↗ |
| 146 | 2007 | William G. Dempsey, Former Executive Vice President, Pharmaceutical Products Group | 594.8K | — | 2.29M | 2.90M | 852.3K | 1.12M | 7.76M | 66.94% | ↗ |
| 147 | 2007 | Holger A. Liepmann, Executive Vice President, Global Nutrition | 671.7K | — | 1.96M | 1.81M | 548.0K | 1.20M | 6.19M | 60.91% | ↗ |
| 148 | 2007 | James L. Tyree, Executive Vice President, Pharmaceutical Products Group | 634.3K | — | 1.98M | 1.76M | 713.7K | 664.9K | 5.75M | 65.02% | ↗ |
| 149 | 2007 | James L. Tyree, Executive Vice President, Pharmaceutical Products | 634.3K | — | 1.98M | 1.76M | 713.7K | 664.9K | 5.75M | 65.02% | ↗ |
| 150 | 2007 | Stephen R. Fussell, Senior Vice President, Human Resources | 454.7K | — | 2.12M | 2.23M | 480.0K | 464.7K | 5.75M | 75.66% | ↗ |
| 151 | 2006 | Miles D. White, Chairman of the Board, Chief Executive Officer and Director | 1.66M | — | 10.56M | 8.48M | 4.05M | 2.16M | 26.92M | 70.74% | ↗ |
| 152 | 2006 | Richard A. Gonzalez, Chief Operating Officer and Director | 973.9K | — | 8.50M | 4.32M | 1.54M | 1.39M | 16.71M | 76.70% | ↗ |
| 153 | 2006 | Richard A. Gonzalez, Former Chief Operating Officer and Director | 973.9K | — | 8.50M | 4.32M | 1.54M | 1.39M | 16.71M | 76.70% | ↗ |
| 154 | 2006 | Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer | 812.9K | — | 1.83M | 1.27M | 1.09M | 1.02M | 6.02M | 51.46% | ↗ |
| 155 | 2006 | Holger Liepmann, Executive Vice President, Global Nutrition | 626.0K | — | 1.69M | 1.33M | 657.0K | 1.38M | 5.69M | 53.10% | ↗ |
| 156 | 2006 | Holger A. Liepmann, Executive Vice President, Global Nutrition | 626.0K | — | 1.69M | 1.33M | 657.0K | 1.38M | 5.69M | 53.10% | ↗ |
| 157 | 2006 | William G. Dempsey, Former Executive Vice President, Pharmaceutical Products Group | 630.6K | — | 1.77M | 1.28M | 756.0K | 1.03M | 5.47M | 55.84% | ↗ |
| 158 | 2006 | William G. Dempsey, Executive Vice President, Pharmaceutical Products Group | 630.6K | — | 1.77M | 1.28M | 756.0K | 1.03M | 5.47M | 55.84% | ↗ |
| 159 | 2006 | Jeffrey M. Leiden, Former President and Chief Operating Officer, Pharmaceutical Products Group and Director | 225.1K | — | 4.05M | — | — | 485.8K | 4.76M | 85.08% | ↗ |
| 160 | 2005 | Miles D. White Chairman of the Board, Chief Executive Officer and Director | 1.61M | 2.65M | 2.96M | 440.8K | — | 519.7K | 8.18M | 41.59% | ↗ |
| 161 | 2005 | Jeffrey M. Leiden, M.D., Ph.D. President and Chief Operating Officer, Pharmaceutical Products Group and Director | 905.9K | 1.00M | 2.15M | 675.7K | — | 364.7K | 5.10M | 55.47% | ↗ |
| 162 | 2005 | Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director | 905.9K | 1.05M | 2.15M | 287.3K | — | 219.5K | 4.62M | 52.87% | ↗ |
| 163 | 2005 | William G. Dempsey Senior Vice President, Pharmaceutical Operations | 591.9K | 613.0K | 431.5K | 478.8K | — | 280.7K | 2.40M | 37.99% | ↗ |
| 164 | 2005 | Thomas C. Freyman Executive Vice President, Finance and Chief Financial Officer | 730.3K | 825.0K | 431.5K | 313.2K | — | 55.6K | 2.36M | 31.62% | ↗ |
| 165 | 2004 | Miles D. White Chairman of the Board, Chief Executive Officer and Director | 1.55M | 2.70M | 2.40M | 224.1K | — | 165.4K | 7.04M | 37.28% | ↗ |
| 166 | 2004 | Jeffrey M. Leiden, M.D., Ph.D. President and Chief Operating Officer, Pharmaceutical Products Group and Director | 875.4K | 1.10M | 1.75M | 313.2K | — | 108.5K | 4.14M | 49.71% | ↗ |
| 167 | 2004 | Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director | 875.4K | 1.10M | 1.75M | 26.1K | — | 97.1K | 3.85M | 46.10% | ↗ |
| 168 | 2004 | Thomas C. Freyman Executive Vice President, Finance and Chief Financial Officer | 617.3K | 685.0K | 349.3K | 41.5K | — | 39.2K | 1.73M | 22.56% | ↗ |
| 169 | 2004 | William G. Dempsey Senior Vice President, Pharmaceutical Operations | 565.8K | 567.5K | 349.3K | 25.3K | — | 112.9K | 1.62M | 23.11% | ↗ |
| 170 | 2003 | Miles D. White Chairman of the Board, Chief Executive Officer and Director | 1.56M | 1.75M | — | 404.3K | — | 162.4K | 3.88M | 10.42% | ↗ |
| 171 | 2003 | Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director | 882.7K | 885.0K | — | 478.8K | — | 95.0K | 2.34M | 20.45% | ↗ |
| 172 | 2003 | Jeffrey M. Leiden, M.D., Ph.D. President and Chief Operating Officer, Pharmaceutical Products Group and Director | 882.7K | 970.0K | — | 19.9K | — | 114.7K | 1.99M | 1.00% | ↗ |
| 173 | 2003 | Thomas C. Freyman Executive Vice President, Finance and Chief Financial Officer | 585.6K | 589.0K | — | 287.3K | — | 37.3K | 1.50M | 19.16% | ↗ |
| 174 | 2003 | William G. Dempsey Senior Vice President, Pharmaceutical Operations | 534.8K | 540.5K | — | 63.8K | — | 100.5K | 1.24M | 5.15% | ↗ |
| 175 | 2002 | Miles D. White Chairman of the Board, Chief Executive Officer and Director | 1.50M | 1.25M | 11.47M | 675.7K | — | 140.9K | 15.03M | 80.79% | ↗ |
| 176 | 2002 | Jeffrey M. Leiden, M.D., Ph.D. President and Chief Operating Officer, Pharmaceutical Products Group and Director | 807.4K | 680.0K | 8.31M | 478.8K | — | 106.2K | 10.39M | 84.66% | ↗ |
| 177 | 2002 | Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director | 802.5K | 505.0K | 8.31M | 478.8K | — | 80.9K | 10.18M | 86.36% | ↗ |
| 178 | 2002 | William G. Dempsey Senior Vice President, International Operations | 501.6K | 375.0K | 1.43M | 250.0K | — | 104.5K | 2.66M | 63.18% | ↗ |
| 179 | 2002 | William G. Dempsey Senior Vice President, Pharmaceutical Operations | 501.6K | 375.0K | 1.43M | 106.4K | — | 104.5K | 2.52M | 61.08% | ↗ |
| 180 | 2002 | Thomas C. Freyman Executive Vice President, Finance and Chief Financial Officer | 493.3K | 375.0K | 1.43M | 55.4K | — | 35.9K | 2.39M | 62.21% | ↗ |
| 181 | 2002 | Thomas C. Freyman Senior Vice President, Finance and Chief Financial Officer | 493.3K | 375.0K | 1.43M | 26.6K | — | 35.9K | 2.36M | 61.75% | ↗ |
| 182 | 2001 | Miles D. White Chairman of the Board, Chief Executive Officer and Director | 1.45M | 2.10M | 2.09M | 525.0K | — | 173.0K | 6.33M | 41.28% | ↗ |
| 183 | 2001 | Jeffrey M. Leiden, M.D., Ph.D. President and Chief Operating Officer, Pharmaceutical Products Group and Director | 619.6K | 700.0K | — | 450.0K | — | 25.0K | 1.79M | 25.08% | ↗ |
| 184 | 2001 | Thomas C. Freyman Executive Vice President, Finance and Chief Financial Officer | 372.8K | 364.0K | 492.5K | 250.0K | — | 18.9K | 1.50M | 49.56% | ↗ |
| 185 | 2001 | Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director | 593.8K | 642.0K | — | 23.8K | — | 79.6K | 1.34M | 1.78% | ↗ |
| 186 | 2001 | Thomas C. Freyman Senior Vice President, Finance and Chief Financial Officer | 372.8K | 364.0K | 492.5K | 90.0K | — | 18.9K | 1.34M | 43.53% | ↗ |
| 187 | 2001 | William G. Dempsey Senior Vice President, Pharmaceutical Operations | 437.7K | 525.0K | — | 90.0K | — | 90.3K | 1.14M | 7.87% | ↗ |
| 188 | 2001 | William G. Dempsey Senior Vice President, International Operations | 437.7K | 525.0K | — | 89.7K | — | 90.3K | 1.14M | 7.85% | ↗ |
| 189 | 2001 | Christopher B. Begley Senior Vice President, Hospital Products | 430.4K | 425.0K | — | 70.0K | — | 128.5K | 1.05M | 6.64% | ↗ |
| 190 | 2000 | Robert L. Parkinson Jr. Retired President, and Chief Operating Officer | 982.8K | 1.09M | — | 350.0K | — | 4.41M | 6.83M | 5.12% | ↗ |
| 191 | 2000 | Jeffrey M. Leiden, M.D., Ph.D. President and Chief Operating Officer, Pharmaceutical Products Group and Director | 276.3K | 555.0K | 3.18M | 250.0K | — | 114.3K | 4.38M | 78.40% | ↗ |
| 192 | 2000 | Miles D. White Chairman of the Board, Chief Executive Officer and Director | 1.39M | 1.80M | — | 223.3K | — | 132.8K | 3.55M | 6.30% | ↗ |
| 193 | 2000 | Richard A. Gonzalez Executive Vice President, Medical Products | 469.7K | 517.0K | 767.2K | 167.1K | — | 54.4K | 1.98M | 47.30% | ↗ |
| 194 | 2000 | Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director | 469.7K | 517.0K | 767.2K | 52.0K | — | 54.4K | 1.86M | 44.04% | ↗ |
| 195 | 2000 | Gary P. Coughlan Senior Vice President, Finance and Chief Financial Officer | 498.9K | 500.0K | — | 250.0K | — | 446.6K | 1.70M | 14.74% | ↗ |
| 196 | 2000 | Joy A. Amundson Senior Vice President, Ross Products | 428.9K | 436.0K | 346.9K | 70.0K | — | 111.1K | 1.39M | 29.93% | ↗ |
| 197 | 2000 | William G. Dempsey Senior Vice President, International Operations | 399.2K | 435.0K | — | 120.0K | — | 56.1K | 1.01M | 11.88% | ↗ |
| 198 | 2000 | Christopher B. Begley Senior Vice President, Hospital Products | 356.4K | 353.0K | — | 10.0K | — | 86.9K | 806.3K | 1.24% | ↗ |
| 199 | 2000 | Thomas C. Freyman Senior Vice President, Finance and Chief Financial Officer | 252.4K | 232.0K | — | 100.0K | — | 14.1K | 598.5K | 16.71% | ↗ |
| 200 | 1999 | Miles D. White Chairman of the Board, Chief Executive Officer and Director | 1.31M | 800.0K | — | 450.0K | — | 95.7K | 2.65M | 16.97% | ↗ |
| 201 | 1999 | Robert L. Parkinson Jr. Retired President, and Chief Operating Officer | 932.7K | 600.0K | — | 57.8K | — | 76.6K | 1.67M | 3.47% | ↗ |
| 202 | 1999 | Christopher B. Begley Senior Vice President, Hospital Products | 296.2K | 222.7K | 760.0K | 250.0K | — | 54.6K | 1.58M | 63.79% | ↗ |
| 203 | 1999 | Gary P. Coughlan Senior Vice President, Finance and Chief Financial Officer | 480.4K | 384.3K | — | 133.7K | — | 309.1K | 1.31M | 10.23% | ↗ |
| 204 | 1999 | Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director | 366.3K | 315.0K | — | 250.0K | — | 37.1K | 968.4K | 25.82% | ↗ |
| 205 | 1999 | Joy A. Amundson Senior Vice President, Ross Products | 412.4K | 370.0K | — | 95.8K | — | 75.6K | 953.7K | 10.04% | ↗ |
| 206 | 1999 | Richard A. Gonzalez Executive Vice President, Medical Products | 366.3K | 315.0K | — | 90.0K | — | 37.1K | 808.4K | 11.13% | ↗ |
| 207 | 1999 | William G. Dempsey Senior Vice President, International Operations | 322.4K | 220.0K | — | 100.0K | — | 30.0K | 672.4K | 14.87% | ↗ |
| 208 | 1998 | Miles D. White Chairman of the Board, Chief Executive Officer and Director | 669.6K | 1.00M | 740.0K | 89.9K | — | 45.4K | 2.54M | 32.61% | ↗ |
| 209 | 1998 | Robert L. Parkinson Jr. Retired President, and Chief Operating Officer | 598.5K | 700.0K | 740.0K | 325.0K | — | 51.2K | 2.41M | 44.11% | ↗ |
| 210 | 1998 | Richard A. Gonzalez Executive Vice President, Medical Products | 308.6K | 300.0K | 1.04M | 23.0K | — | 33.1K | 1.70M | 62.27% | ↗ |
| 211 | 1998 | Joy A. Amundson Senior Vice President, Ross Products | 382.7K | 360.0K | 740.0K | 80.0K | — | 65.1K | 1.63M | 50.37% | ↗ |
| 212 | 1998 | Gary P. Coughlan Senior Vice President, Finance and Chief Financial Officer | 463.8K | 465.0K | — | 320.0K | — | 276.6K | 1.53M | 20.98% | ↗ |
| 213 | 1998 | William G. Dempsey Senior Vice President, International Operations | 263.8K | 220.0K | 962.0K | 26.6K | — | 10.3K | 1.48M | 66.68% | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert Ford | Chairman, Pres & Chief Executive Officer | 4M | male |
| Elizabeth Cushman | Executive Vice President, General Counsel & Secretary | 3M | female |
| Lisa D. Earnhardt | Executive Vice President & Group President of Medical Devices | 2M | female |
| Philip Boudreau | Chief Financial Officer & Executive Vice President of Finance | 2M | male |
| Christopher J. Scoggins | Executive Vice President of Diabetes Care | 2M | male |
| Daniel Gesua Sive Salvadori | Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products | 2M | male |
| Sabina Ewing | Senior Vice President of Business & Technology Services and Chief Information Officer | — | female |
| Erica L. Battaglia | Vice President and Chief Ethics & Compliance Officer | — | — |
| Melissa Brotz | Senior Vice President of Global Marketing & External Affairs | — | female |
| Michael Comilla | Vice President of Investor Relations. | — | male |
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-02-24 | 2025-03-06 | Shelley Moore Capito | WV | Spouse | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-01-08 | 2025-01-31 | Markwayne Mullin | OK | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2024-12-11 | 2024-12-31 | Markwayne Mullin | OK | Joint | Sale (Partial) | $15,001 - $50,000 | ↗ |
| 2024-01-17 | 2024-02-02 | Thomas R. Carper | DE | Spouse | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2023-10-03 | 2023-11-01 | Markwayne Mullin | OK | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2023-09-21 | 2023-10-20 | Pete Ricketts | NE | Spouse | Sale (Full) | $100,001 - $250,000 | ↗ |
| 2023-09-13 | 2023-10-12 | Markwayne Mullin | OK | Joint | Purchase | $15,001 - $50,000 | ↗ |
| 2022-10-17 | 2022-11-03 | Thomas R. Carper | DE | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2020-04-07 | 2020-05-01 | Kelly Loeffler | GA | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2020-03-03 | 2020-04-29 | Shelley Moore Capito | WV | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2019-04-09 | 2019-04-24 | Tina Smith | MN | Joint | Sale (Full) | $250,001 - $500,000 | ↗ |
| 2018-04-24 | 2019-05-09 | Shelley Moore Capito | WV | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2018-04-05 | 2018-05-14 | Shelley Moore Capito | WV | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2017-10-24 | 2018-10-26 | Bill Cassidy | LA | Spouse | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2017-10-18 | 2017-11-07 | Tammy Duckworth | IL | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2017-02-23 | 2017-03-15 | Sheldon Whitehouse | RI | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2016-11-15 | 2016-12-12 | Sheldon Whitehouse | RI | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2016-04-19 | 2016-05-04 | Shelley Moore Capito | WV | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2016-03-31 | 2017-12-06 | Bill Cassidy | LA | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2015-07-21 | 2015-08-03 | Shelley Moore Capito | WV | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-03-24 | 2026-04-20 | Laura Friedman | — | — | Exchange | $1,001 - $15,000 | ↗ |
| 2026-03-19 | 2026-04-07 | Richard Dean Dr McCormick | GA06 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2026-03-04 | 2026-04-10 | Michael McCaul | TX10 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2026-02-10 | 2026-03-10 | Gilbert Cisneros | CA31 | — | Sale | $1,001 - $15,000 | ↗ |
| 2026-01-29 | 2026-02-20 | Thomas H. Kean | NJ07 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-12-19 | 2026-01-12 | Gilbert Cisneros | CA31 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-12-18 | 2026-01-16 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-12-08 | 2026-01-13 | Julia Letlow | LA05 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-12-04 | 2026-01-08 | Byron Donalds | FL19 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-11-18 | 2025-12-15 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-11-13 | 2025-12-12 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-11-05 | 2025-12-10 | Rich McCormick | — | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-10-30 | 2025-11-14 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-10-06 | 2025-10-17 | Rick Larsen | WA02 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-08-14 | 2025-09-12 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-08-06 | 2025-09-12 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-07-21 | 2025-08-21 | Thomas H. Kean | NJ07 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-07-18 | 2025-08-12 | Josh Gottheimer | NJ05 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-07-10 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-07-10 | 2025-08-14 | Lisa McClain | MI09 | Spouse | Sale | $1,001 - $15,000 | ↗ |
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ABT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
